


Dietary Interventions in Liver Disease

Foods, Nutrients, and Dietary Supplements

Edited by Ronald Ross Watson and Victor R. Preedy



Dietary Interventions in Liver Disease

Foods, Nutrients, and Dietary Supplements

Edited by

Ronald Ross Watson

Victor R. Preedy



ACADEMIC PRESS

An imprint of Elsevier

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

Copyright © 2019 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

ISBN: 978-0-12-814466-4

For information on all Academic Press publications visit our website at <https://www.elsevier.com/books-and-journals>



Publisher: Stacy Masucci

Acquisition Editor: Stacy Masucci

Editorial Project Manager: Megan Ashdown

Production Project Manager: Punithavathy Govindaradjane

Cover Designer: Mark Rogers

Typeset by TNQ Technologies

Contents

List of Contributors	xv
Acknowledgments	xix

Section I Overview of Liver Health

1. Genome-Based Nutrition in Chronic Liver Disease

*Sonia Roman, Ingrid Rivera-Iñiguez,
Claudia Ojeda-Granados,
Maricruz Sepulveda-Villegas
and Arturo Panduro*

1. Introduction	3
1.1 Chronic Liver Disease	3
1.2 Hepatopathogenic Diet and Its Variations by Liver Disease Etiology	3
2. Genome-Based Nutrition: A Regionalized and Personalized Diet	4
3. Genes, Microbiota, and Regionalized Diet	5
4. Nutritional Intervention in Chronic Liver Disease	5
4.1 Nonalcoholic Fatty Liver Disease—Nonalcoholic Steatohepatitis	6
4.2 Alcoholic Liver Disease	8
4.3 Hepatitis C Virus Infection	9
5. Concluding Remarks	11
List of Abbreviations	11
Glossary	12
References	12

2. Current Therapeutic Strategies for Alcoholic Liver Disease

*Alaa El-Din El-Sayed El-Sisi,
Samia Salim Sokar and
Dina Zakaria Mohamed*

1. Introduction	15
2. Pathogenesis of Alcoholic Liver Disease	16
2.1 Alcoholic Fatty Liver (Steatosis)	16
2.2 Alcoholic Hepatitis	16

2.3 Alcoholic Fibrosis	16
2.4 Alcoholic Cirrhosis	17
3. Current Therapies for Alcoholic Liver Disease	17
3.1 Abstinence and Lifestyle Modification	17
3.2 Nutritional Support and Supplements	17
3.3 Pharmacological Drugs and New Agents That Are Under Development	17
3.4 Liver Transplantation	20
3.5 Natural and Herbal Medicines for the Prevention and Treatment of ALD	20
3.6 Herbal Formulas for Treatment of Alcoholic Liver Disease	20
3.7 The Combination Therapies of Drugs and Natural Agents	25
Endnotes	25
References	25

3. Features of Hepatic Encephalopathy

Mohamed M. Amin

1. Introduction	31
2. Pathogenesis	31
2.1 Ammonia Assumption	31
2.2 Gamma-Aminobutyric Corrosive Assumption	32
2.3 Changeability of Hepatic Encephalopathy	32
3. Clinical Features of Hepatic Encephalopathy	32
4. Laboratory Irregularities in Hepatic Encephalopathy	33
5. Regular Precipitants of Hepatic Encephalopathy	33
6. Distinguishable Diagnosis for Hepatic Encephalopathy	34
7. Controlling of Hepatic Encephalopathy	34
7.1 Methodology Respects	34
7.2 Medications to Decrease Intestinal Ammonia Production	34

7. Phytochemicals in the Prevention of Ethanol-Induced Hepatotoxicity: A Revisit

*Manjeshwar Shrinath Baliga,
Arnadi Ramachandrayya Shivashankara,
Sunitha Venkatesh, Harshith P. Bhat,
Princy Louis Palatty,
Ganesh Bhandari and Suresh Rao*

1. Introduction	79
2. Phytochemicals in the Protection of Alcohol-Induced Hepatotoxicity	79
2.1 Beta-Carotene	79
2.2 Lutein	80
2.3 Meso-Zeaxanthin	81
2.4 Betaine	81
2.5 Ferulic Acid	82
2.6 Ellagic Acid	83
2.7 Epigallocatechin-3-Gallate	83
2.8 Quercetin	84
2.9 Morin	84
2.10 Hydroxystilbenes and Resveratrol	84
2.11 Ursolic Acid	85
2.12 Andrographolide and Arabinogalactan Proteins of <i>Andrographis paniculata</i> Nees	85
2.13 Picroliv	85
2.14 Silymarin	85
3. Mechanisms	86
4. Conclusions	86
List of Abbreviations	86
References	87

8. Protective Actions of Polyphenols in the Development of Nonalcoholic Fatty Liver Disease

Yoojin Lee and Ji-Young Lee

1. Introduction	91
2. Pathogenesis and Progression of NAFLD	91
2.1 Liver Steatosis	91
2.2 Hepatic Oxidative Stress, Inflammation, and Apoptosis	92
2.3 Liver Fibrosis	93
3. Polyphenols in Foods and Natural Products	93
4. Protective Action of Polyphenols Against NAFLD Progression	94
4.1 Quercetin	94
4.2 Epigallocatechin-3-O-Gallate	94
4.3 Anthocyanins	95
4.4 Resveratrol	95
5. Conclusion	96
References	96

9. Phytotherapy for the Liver

Erika Ramos-Tovar and Pablo Muriel

1. Introduction	101
2. Liver Disease Treatment	101
3. Plant-Derived Compounds With Liver Beneficial Properties	101
4. <i>Curcuma longa</i>	102
4.1 Antiinflammatory Properties	102
4.2 Antifibrotic Properties	102
4.3 Anticancer Properties of Curcumin	103
4.4 Antiheavy Metal Properties of Curcumin in the Liver	103
4.5 Antisteatotic Properties of Curcumin	103
5. <i>Silybum marianum</i>	103
5.1 Antiinflammatory and Immunomodulation Activities	104
5.2 Silymarin Prevents Fibrosis	104
5.3 Beneficial Effects of Silymarin on NAFLD	104
5.4 Anticancer Properties of Silymarin	104
6. Quercetin	105
6.1 Quercetin Inhibits Liver Inflammation	105
6.2 Quercetin and Hepatic Fibrosis	105
6.3 Quercetin and Nonalcoholic Steatohepatitis	106
6.4 Quercetin and Hepatocellular Carcinoma	106
7. Naringenin	106
7.1 Antiinflammatory Properties of Naringenin	106
7.2 Naringenin Antifibrogenic Effects	107
7.3 Naringenin and Hepatocellular Carcinoma	107
8. Coffee	107
9. Stevia	108
10. Resveratrol	108
11. L-Theanine	108
12. Hesperidin	109
13. Colchicine	109
14. Rosemary	109
15. Glycyrrhizin (Glycyrrhizic Acid)	109
16. Other Plant-Derived Compounds	110
17. Conclusions and Perspectives	110
Acknowledgments	114
References	114

Section III Herbs and Plants for Treating Liver Disease

10. *Curcuma longa*, the Polyphenolic Curcumin Compound and Pharmacological Effects on Liver

*Bui Thanh Tung, Dong Thi Nham,
Nguyen Thanh Hai and Dang Kim Thu*

1. Introduction of <i>Curcuma longa</i>	125
1.1 Chemical Composition in the Rhizome of <i>Curcuma longa</i> L.	125
2. The Polyphenolic Curcumin Compound	127
2.1 The Therapeutic Potential of <i>Curcuma longa</i> Components	127
2.2 Antibacterial Activity	127
2.3 Antioxidant Activity	127
2.4 Anti-inflammatory Activity	128
2.5 For Treatment of Arthritis	128
2.6 For Treatment of Metabolic Syndrome	129
2.7 For Treatment of Cancer	130
3. Curcumin and Liver Disease	131
3.1 Curcumin Against Heavy Metals–Induced Liver Damage	131
3.2 The Effects of Curcumin in Preclinical In Vitro and In Vivo HCC	131
3.3 Hepatitis B Virus	132
4. Conclusions	132
List of Abbreviations	132
References	133

11. *Nymphaea alba* and Liver Protection

Riham O. Bakr

1. Introduction	135
2. Traditional Uses	135
3. Phytoconstituents	136
3.1 Flower Phytoconstituents	136
3.2 Leaf Phytoconstituents	136
3.3 Rhizome Phytoconstituents	137
4. Validated Studies	137
4.1 Hepatoprotective Effect of Flowers and a Powerful Anti-Inflammatory Activity	138
4.2 Leaf Extract and Potent Biological Activities	139
4.3 Rhizomes' Biological Activities	139
5. Phenolics of <i>N. alba</i> and Liver Protection	140

6. Conclusion	141
List of Abbreviations	141
References	142

12. The Flavone Baicalein and Its Use in Gastrointestinal Disease

Yangchun Xie, Rui Kang and Daolin Tang

1. Introduction	145
2. Extraction and Purification	145
3. Metabolism and Conversion	145
4. Use of Baicalein in Gastrointestinal Disease	146
4.1 Ulcerative Colitis	146
4.2 Gastric Ulceration	146
4.3 Ischemia-Reperfusion Injury	146
4.4 Liver Fibrosis	147
4.5 Cancer Prevention and Therapy	147
4.6 Colorectal Cancer	147
4.7 Pancreatic Cancer	147
4.8 Gastric Cancer	147
4.9 Hepatocellular Carcinoma	148
4.10 Diabetes Mellitus	148
5. Mechanism of Action of Baicalein	148
5.1 Regulation of Cell Death	148
5.2 Regulation of Signaling Transduction	149
6. Conclusion	151
Acknowledgments	151
References	151

13. Pyrroloquinoline Quinone: Its Profile, Effects on the Liver and Implications for Health and Disease Prevention

Karen R. Jonscher and Robert B. Rucker

1. Introduction: Pyrroloquinoline Quinone	157
2. Factors Contributing to the Development of NAFLD/NASH	161
3. Systemic Effects of PQQ on NAFLD/NASH	162
3.1 Mechanistic Modes of Action	162
3.2 Pyrroloquinoline Quinone as an Antioxidant	162
3.3 Pyrroloquinoline Quinone and Lipid Metabolism	162
3.4 Pyrroloquinoline Quinone and Inflammation	165
3.5 Pyrroloquinoline Quinone and the Microbiome	165
3.6 Pyrroloquinoline Quinone and Fibrosis	166

4. Human Studies and Implications for Health	167	3. Validated Uses	183
4.1 Pyrroloquinoline Quinone and Cognition	167	4. Tea Protects Against the Alcohol-Induced Hepatotoxicity	184
4.2 Pyrroloquinoline Quinone and Skin Elasticity	167	5. Tea Protects Against Carbon Tetrachloride-Induced Hepatotoxicity	185
4.3 Pyrroloquinoline Quinone and Metabolism	168	6. Effect of Tea on <i>N</i> -Acetaminophen-Induced Hepatotoxicity	186
5. Conclusions	168	7. Tea Is Effective in Viral Hepatitis	186
References	168	8. Effect of Tea on Ischemia-Reperfusion Injury	186
		9. Effect of Tea on Fatty Liver Disease	186
14. Herbal Weight Loss Supplements: From Dubious Efficacy to Direct Toxicity		10. Effect of Tea on Hepatotoxicity of Lead	187
<i>Armando E. González-Stuart and José O. Rivera</i>		11. Effect of Tea on Hepatotoxicity of Arsenic	187
1. Introduction	175	12. Effect of Tea on Phenobarbitol-Induced Liver Damage	187
2. The Surge of Herbal Product Use Within Complementary and Alternative Medicine	175	13. Effect of Tea on Hepatotoxicity of Microcystin	187
3. The Internet as a Source of Information About Herbal Weight Loss Supplements	176	14. Effect of Tea on Hepatotoxicity of Aflatoxins	187
4. Herbal Supplement Identity, Efficacy, and Safety: Bedlam in the Cyber Marketplace	176	15. Effect of Tea on Hepatotoxicity of Azathioprine	188
5. Mexican Hawthorn Root	176	16. Effect of Tea on Galactosamine- and Lipopolysaccharide-Induced Liver Damage	188
5.1 Yellow Oleander or "Codo de Fraile"	177	17. Effect of Tea on Hepatotoxicity of Insecticides	188
6. Toxicity of <i>Thevetia</i> spp.	177	18. Effect of Tea on Hepatocarcinogenesis	189
7. Candlenut Tree Seed	178	19. Conclusions	189
8. Botanical Characteristics	178	List of Abbreviations	190
9. Use of the Candlenut Tree in Asian Traditional Medicine	178	References	190
10. Weight Loss and Other Health Claims Made on the Internet for Candlenut Tree Seeds	179		
11. International Health Agencies Ban Candlenut Seed Due to Its Toxicity	179	16. Hepatoprotective Effects of the Indian Gooseberry (<i>Emblica officinalis</i> Gaertn): A Revisit	
12. Conclusions	179	<i>Manjeshwar Shrinath Baliga, Arnadi Ramachandrayya Shivashankara, K.R. Thilakchand, M.P. Baliga-Rao, Princy Louis Palatty, Thomas George and Suresh Rao</i>	
References	180	1. Introduction	193
15. Tea (<i>Camellia sinensis</i> L. Kuntze) as Hepatoprotective Agent: A Revisit		2. Phytochemicals	193
<i>Arnadi Ramachandrayya Shivashankara, Suresh Rao, Thomas George, Soniya Abraham, Marshal David Colin, Princy Louis Palatty and Manjeshwar Shrinath Baliga</i>		3. Traditional Uses	193
1. Introduction	183	4. Scientifically Validated Studies	194
2. Phytochemistry of Tea	183	5. Effect of Amla on Hepatotoxicity of Ethanol	195
		6. Effect of Amla on Hepatotoxicity of Heavy Metals Arsenic and Cadmium	195
		7. Effect of Amla on Hepatotoxicity of Iron Overload	196
		8. Effect of Amla on Hepatotoxicity of Ochratoxin	196
		9. Effect of Amla on Hepatotoxicity of Antitubercular Drugs	196

10. Effect of Amla on Hepatotoxicity of Hexachlorocyclohexane	196	16. Bile Acids and Fiber	209
11. Effect of Amla on Hepatotoxicity of Carbon Tetrachloride	196	17. Prebiotics and Probiotics	209
12. Effect of Amla on Hepatotoxicity of Paracetamol	197	18. The Mediterranean and Other Diets	210
13. Effect of Amla Phytochemicals on Galactosamine- and Lipopolysaccharide-Induced Liver Damage	197	19. Zinc	210
14. Effect of Amla Phytochemicals on Hepatotoxicity of Microcystin	197	20. Niacin (Nicotinic Acid)	210
15. Effect of Amla on Hepatocarcinogenesis	197	21. Astaxanthin	210
16. Effect of Amla on Hepatic Lipid Metabolism and Metabolic Syndrome	198	22. Curcumin	210
17. Effect of Amla on Nonalcoholic Fatty Liver Disease	198	23. Conclusion	210
18. Mechanism of Action(s) Responsible for the Hepatoprotective Effects	198	References	211
19. Conclusions	199		
List of Abbreviations	199		
References	200		
Further Reading	201		

Section IV Dietary Macronutrients and Micronutrients for Healthy Liver Function

17. Major Dietary Interventions for the Management of Liver Disease

Idris Adewale Ahmed

1. Introduction	205
2. Liver as an Organ	206
3. Liver Failure	206
4. Causes of Hepatic Injury	206
5. Nonalcoholic Fatty Liver Disease	206
6. Alcoholic Liver Disease	207
7. Chronic Hepatitis B and Chronic Hepatitis C	207
8. Hepatocellular Carcinoma	207
9. Dietary Interventions in the Management of Liver Diseases	208
10. Diet Types	208
11. Fat	208
12. Protein	208
13. Carbohydrates	208
14. Glycemic Index	209
15. Antioxidants	209

18. The Effects of Dietary Advanced Glycation End Products (AGEs) on Liver Disorders

Fahimeh Agh and Farzad Shidfar

1. Advanced Glycation End Products	213
2. Circulating AGEs and Liver Disorders	215
3. The AGEs–RAGE System in Liver Disorders	216
4. The Effects of Dietary AGEs on Liver Disorders	218
4.1 Liver Histology	218
4.2 Liver Enzymes	221
4.3 Metabolic and Inflammatory Profiles	221
4.4 Reactive Oxygen Species Production	222
4.5 Receptor for Advanced Glycation End Products	223
4.6 De Novo Lipogenesis	223
4.7 Weight Gain	224
5. Dietary Interventions to Reduce the AGEs	224
6. Summary	224
List of Abbreviations	227
References	228

19. Molecular Mechanisms of the Protective Role of Wheat Germ Oil Against Oxidative Stress–Induced Liver Disease

El-Sayed Akool

1. Introduction	233
2. Reactive Oxygen Species and Liver Diseases	233
3. Wheat Germ Oil and Liver Diseases	235
3.1 Nutritional Composition	235
3.2 Antioxidant Activity	235
References	236

20. Critical Role of Hepatic Fatty-Acyl Phospholipid Remodeling in Obese and Nonobese Fatty Liver Mouse Models

Walee Chamulitrat, Gerhard Liebisch, Anita Pathil and Wolfgang Stremmel

1. Introduction	239
1.1 Causes of Obesity: Genetics and Diets	239
1.2 Consequence of Obesity: NAFLD and NASH	239
1.3 Animal Models of Obese and Nonobese NAFLD/NASH	240
1.4 Comparison of Hepatic Lipids Among Obese and Nonobese NAFLD/NASH	241
2. Phospholipids in NAFLD and NASH	241
2.1 Linking Hepatic Triglyceride to Phospholipid in NAFLD	241
2.2 Comparison of Hepatic Phospholipid Among Obese and Nonobese NAFLD/NASH	241
2.3 Comparison of Hepatic Phospholipid Ratios Among Obese and Nonobese NAFLD/NASH	243
3. Phospholipid-Metabolizing Genes in Obesity and NAFLD	244
3.1 PLA2G6 or iPLA2 β in Obesity and NAFLD	245
3.2 Effects of iPLA2 β Deficiency on Phospholipids in Obese Ob/Ob and HFD-Fed Mice	245
3.3 Effects of iPLA2 β Deficiency on Phospholipids in MCD-Fed Mice	247
4. Summarized Findings and Proposed Mechanisms	247
5. Perspectives	251
5.1 Use of iPLA2 β Antagonists for Steatosis Protection in Obese Versus Nonobese NAFLD	251
5.2 Considerations and Precautions	252
6. Conclusions	252
List of Abbreviations	252
Acknowledgments	253
References	253

21. Vitamin D3 and Liver Protection

Malath Azeez Al-Saadi

1. Introduction	257
1.1 Mechanism of Action	257

2. Materials and Methods	258
2.1 Drugs	258
2.2 Study Design	258
2.3 Induction of Acute Hepatotoxicity	258
2.4 Statistical Analysis	258
3. Results	259
4. Discussion	259
References	260

22. The Role of Carbohydrate Response Element-Binding Protein in the Development of Liver Diseases

Katsumi Iizuka

1. Introduction	263
2. ChREBP, a Glucose-Activated Transcription Factor That Regulates Glucose and Lipid Metabolism	263
3. Dietary Composition and ChREBP	263
4. ChREBP and Liver Diseases	264
4.1 Nonalcoholic Fatty Liver Disease	264
4.2 Alcoholic Liver Disease	265
4.3 Liver Tumors	267
4.4 Virus Infection	267
4.5 Glycogen Storage Diseases	268
5. Supplement and ChREBP	268
5.1 Polyunsaturated Fatty Acids	268
5.2 Ketone Bodies	269
5.3 Vinegar (Acetic Acid)	269
5.4 Polyphenols	269
6. Conclusion	270
Acknowledgments	270
References	271

23. Trans Fatty Acid in the Liver and Central Nervous System

Rafael Longhi

1. Introduction	275
2. Hydrogenation Process	275
3. Biochemical Metabolism	276
4. Trans Fatty Acids and Liver Damage	276
4.1 Cell Culture	276
4.2 Animal Models	277
4.3 Human Trials	279
5. Trans Fatty Acids and the Central Nervous System	280
5.1 Animal Studies	281
5.2 Human Trials	283
6. Final Considerations	284
References	284

24. Fish Oil Supplements During Perinatal Life: Impact on the Liver of Offspring

Emilio Herrera and Encarnación Amusquivar

- | | |
|--|-----|
| 1. Introduction | 287 |
| 2. Role of Fatty Acids in Fetal Development | 287 |
| 3. Fatty Acids and Epigenetics | 288 |
| 4. Fish Oil Supplements During Pregnancy | 288 |
| 5. Prevalence and Pathogenic Aspects of Nonalcoholic Fatty Liver Disease | 290 |
| 6. Fetal Programming Origins of NAFLD | 290 |
| 7. Potential Protective Role of Fish Oil in the NAFLD Development | 291 |
| Acknowledgments | 292 |
| References | 292 |

25. Purple Rice Bran Improves Hepatic Insulin Signaling via Activation of Akt and Stabilization of IGF in Diabetic Rats

Ei Ei Hlaing, Supicha Rungcharoenarrichit, Narissara Lailerd, Sittiruk Roytrakul and Pichapat Piamrojaphat

- | | |
|--|-----|
| 1. Introduction | 297 |
| 2. Methods | 298 |
| 2.1 Tissue Preparation and Homogenization | 298 |
| 2.2 Determination of Tissue Protein Concentration | 298 |
| 2.3 One-Dimensional SDS-PAGE Analysis | 298 |
| 2.4 In-Gel Tryptic Digestion Before LC-MS/MS Analysis | 298 |
| 2.5 Peptide Identification and Quantitation by LC-MS/MS Analysis | 299 |
| 2.6 Bioinformatics Analysis | 299 |
| 2.7 Confirmation of Candidate Genes and Their Affected Proteins | 299 |
| 2.8 mRNA Level of Affected Genes by Quantitative Real-Time PCR | 300 |
| 2.9 Affected Protein Expression Level by Western Blot Analysis | 300 |
| 2.10 Statistical Analysis | 300 |
| 3. Results | 300 |
| 3.1 LC-MS/MS Analysis and Hepatic Proteins Identification | 300 |

- | | |
|--|-----|
| 3.2 Functional Categories of Identified Hepatic Proteins of Diabetic Rats and Diabetic Rats With Purple Rice Bran Supplement | 301 |
| 3.3 Bioinformatic Analysis of Unique Proteins Found in the Hepatic Tissues of Diabetic Rats and Diabetic Rats With Purple Rice Bran Supplement | 303 |
| 3.4 mRNA Expression Level of Candidate Genes of Diabetic Rats' Liver | 304 |
| 3.5 mRNA Expression Level of <i>Rangap1</i> Gene | 304 |
| 3.6 mRNA Expression Level of Candidate Genes of Purple Rice Bran-Supplemented Diabetic Rats' Liver | 304 |
| 3.7 mRNA Expression Level of Affected Genes From Hepatic Proteomic Analysis | 304 |
| 3.8 Protein Expression Level of Affected Proteins From Hepatic Proteomic Analysis | 305 |
| 4. Discussion and Conclusion | 305 |
| Acknowledgments | 312 |
| References | 312 |
| Further Reading | 312 |

Section V Toxic Dietary Materials Including Alcohol-Induced Liver Dysfunction: Treatment

26. Heavy Metals and Low-Oxygen Microenvironment—Its Impact on Liver Metabolism and Dietary Supplementation

Kusal K. Das, Rajesh Honnutagi, Lata Mullur, R. Chandramouli Reddy, Swastika Das, Dewan Syed Abdul Majid and M.S. Biradar

- | | |
|--|-----|
| 1. Introduction | 315 |
| 2. Heavy Metals and Its Interactions | 317 |
| 2.1 Heavy Metal Toxicities: Nickel and Lead | 317 |
| 3. Hypoxia Pathophysiology | 318 |
| 3.1 Hypoxia Microenvironment | 318 |
| 3.2 Hypoxia and Heavy Metals (Nickel and Lead) | 318 |

4. Heavy Metals in Liver Diseases	319	28. Beneficial Effects of Natural Compounds on Heavy Metal-Induced Hepatotoxicity	
4.1 Heavy Metals and Liver Pathophysiology (Nickel and Lead)	319	<i>Parisa Hasanein and Abbasali Emamjomeh</i>	
4.2 Possible Mechanism of Altered Hepatocellular Architecture by Heavy Metals	321	1. Introduction	345
5. Hypoxia and Liver Diseases	321	2. Arsenic Hepatotoxicity	346
5.1 Hypoxia—Liver Histopathology	322	2.1 Mechanisms of Arsenic-Induced Hepatotoxicity	346
5.2 Hypoxia and Heavy Metals (Nickel and Lead)—Liver Histopathology	323	3. Cadmium Hepatotoxicity	346
6. Heavy Metals (Nickel and Lead), Hypoxia, and Liver Functions—Role of Dietary Supplementations	323	3.1 Mechanisms of Cadmium-Induced Hepatotoxicity	347
6.1 Heavy Metals, Liver Functions, and Dietary Supplementation	324	4. Chromium Hepatotoxicity	347
6.2 Hypoxia, Liver Function, and Dietary Supplementation	324	4.1 Mechanisms of Chromium-Induced Hepatotoxicity	347
6.3 Heavy Metals, Hypoxia, and Liver Functions—Dietary Supplementation	325	5. Copper Hepatotoxicity	348
7. Conclusion	328	5.1 Mechanisms of Copper-Induced Hepatotoxicity	348
Acknowledgments	329	6. Lead Hepatotoxicity	348
References	329	6.1 Mechanisms of Lead-Induced Hepatotoxicity	348
27. Cadmium and Fullerenes in Liver Diseases		7. Mercury Hepatotoxicity	349
<i>Sinisa Djurasevic, Zoran Todorovic, Sladjan Pavlovic and Snezana Pejic</i>		7.1 Mechanisms of Mercury-Induced Hepatotoxicity	349
1. Introduction	333	8. Effects of Natural Products on Heavy Metal-Induced Hepatotoxicity	350
1.1 Cytochromes P450	333	8.1 Vitamins C and E	350
1.2 Xenobiotic Metabolism and Hepatotoxicity	334	8.2 Curcumin	350
2. Liver and Oxidative Stress	335	8.3 N-Acetylcysteine	350
2.1 Oxidative Stress and Liver Disorders	335	8.4 α -Lipoic Acid	351
3. Cadmium as the Model of Hepatotoxicity	336	8.5 Melatonin	351
3.1 Molecular Mechanisms of Cadmium Toxicity	337	8.6 Flavonoid-Rich Extracts	351
3.2 Cadmium and Oxidative Stress	337	8.7 Anthocyanidins	352
3.3 Cadmium and Liver Injury in Animals	338	8.8 Quercetin	352
3.4 Cadmium and Mitochondria	338	8.9 Naringenin	352
4. Fullerenes and Liver Protection	338	8.10 Black Tea	352
4.1 Chemical Properties of Fullerenes	338	8.11 Olive Oil	352
4.2 Pharmacological Properties of Fullerenes	339	8.12 Sesame Oil	352
4.3 Fullerenes as the Protectors in the Carbon Tetrachloride Model of Liver Toxicity	339	8.13 Combination Therapy	352
Acknowledgments	340	References	353
References	340	29. Nutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease	
		<i>Cindy X. Cai, Stella Carlos, Pejman Solaimani, Bansari J. Trivedi, Chuong Tran and Shobha Castelino-Prabhu</i>	
		1. Introduction	357
		2. Epidemiology	357
		3. Risk Factors	357
		4. Pathogenesis	358
		5. Clinical Manifestations	360
		6. Histopathology	360

7. Diagnosis	360	4. Hepatic Fructose Metabolism	374
8. Natural Course and Outcomes	361	5. Fructose, the Common Etiological Factor of NAFLD	374
9. Treatment	361	6. Management of NAFLD	376
9.1 Lifestyle Modification for NAFLD	361	7. Pharmacotherapy	376
9.2 Pharmacological Treatment	365	8. Lifestyle Intervention	376
9.3 Bariatric Surgery and Endoscopic Bariatric Intervention	366	9. Dietary Fat	376
10. Conclusions	366	10. Metabolic Fate of n-3 Long-Chain PUFA: Bioactive Lipid Mediators	378
References	367	11. Eicosapentaenoic Acid (EPA; C20:5n-3)-Derived Lipid Mediators	378
30. Dietary Management of Nonalcoholic Fatty Liver Disease (NAFLD) by n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation: A Perspective on the Role of n-3 PUFA-Derived Lipid Mediators		12. Docosahexaenoic Acid (DHA; C22:6n-3)-Derived Lipid Mediators	378
<i>SM Jeyakumar and A Vajreswari</i>		13. n-3 PUFA and NAFLD	379
1. Background	373	14. Lipid Mediators of n-3 PUFA and NAFLD	382
2. NAFLD—Worldwide Burden	373	15. Conclusion	384
3. Dietary Carbohydrates: A Glance at Fructose	374	Acknowledgments	384
		References	384
		Index	391

List of Contributors

- Soniya Abraham** Undergraduate student, Father Muller Medical College, Mangalore, India
- Fahimeh Agh** Department of Nutrition, School of Health, Iran University of Medical sciences, Tehran, Iran
- Idris Adewale Ahmed** Department of Biotechnology, Faculty of Science, Lincoln University College Malaysia, Petaling Jaya, Malaysia
- El-Sayed Akool** Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
- Malath Azeez Al-Saadi** Basic Science\Pharmacology-Dentistry College, University of Babylon, Al-hilla, Babil, Iraq
- Mohamed M. Amin** Department of Pharmacology, Medical Division, National Research Centre, Giza, Egypt
- Encarnación Amusquivar** Department of Biochemistry and Chemistry, University San Pablo CEU, Madrid, Spain
- Riham O. Bakr** Pharmacognosy Department, Faculty of Pharmacy, October University for Modern Sciences and Arts, Giza, Egypt
- Manjeshwar Shrinath Baliga** Department of Research, Mangalore Institute of Oncology, Mangalore, India
- M.P. Baliga-Rao** Department of Research, Mangalore Institute of Oncology, Mangalore, India
- Ganesh Bhandari** Undergraduate student, Father Muller Medical College, Mangalore, India
- Harshith P. Bhat** Mangalore Institute of Oncology, Mangalore, India
- M.S. Biradar** Department of Medicine, Shri B.M. Patil Medical College, Hospital and Research Centre, BLDE Deemed to be University, Vijayapur, India
- Flavio A. Cadejani** Division of Endocrinology and Metabolism, Department of Medicine, Federal University of São Paulo, São Paulo, Brazil; Corpometria Institute, Centro Clínico Advance, Brasília, Brazil
- Cindy X. Cai** Division of Gastroenterology and Hepatology, Department of Internal Medicine, VA Loma Linda Healthcare System, Loma Linda University, Loma Linda, CA, United States
- Stella Carlos** Department of Nutrition Services, VA Loma Linda Healthcare System, Loma Linda, CA, United States
- Shobha Castelino-Prabhu** Department of Pathology, VA Loma Linda Healthcare System, Loma Linda, CA, United States
- Walee Chamulitrat** Department of Internal Medicine IV, University of Heidelberg Hospital, Heidelberg, Germany
- Marshal David Colin** Undergraduate student, Father Muller Medical College, Mangalore, India
- Kusal K. Das** Laboratory of Vascular Physiology and Medicine, Department of Physiology, Shri B.M. Patil Medical College, Hospital and Research Centre, BLDE Deemed to be University, Vijayapur, India
- Swastika Das** Department of Chemistry, BLDE Association's, Dr. P.G. Halakatti College of Engineering and Technology, Vijayapur, India
- Sinisa Djurasevic** University of Belgrade Faculty of Biology, Belgrade, Serbia
- Alaa El-Din El-Sayed El-Sisi** Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt
- Abbasali Emamjomeh** Computational Biotechnology Lab (CBB), Department of Plant Breeding and Biotechnology (PBB), University of Zabol, Zabol, Iran
- Junichi Fujii** Department of Biochemistry and Molecular Biology, Graduate School of Medical Science, Yamagata University, Yamagata, Japan
- Thomas George** Undergraduate student, Father Muller Medical College, Mangalore, India
- Armando E. González-Stuart** School of Pharmacy-University of Texas at El Paso, El Paso, TX, United States
- Nguyen Thanh Hai** School of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam
- Parisa Hasanein** Department of Biology, School of Basic Sciences, University of Zabol, Zabol, Iran
- Emilio Herrera** Department of Biochemistry and Chemistry, University San Pablo CEU, Madrid, Spain

- Ei Ei Hlaing** Department of Biochemistry, Chiang Mai University, Chiang Mai, Thailand; Department of Biochemistry, University of Medicine, Mandalay, Myanmar
- Takujiro Homma** Department of Biochemistry and Molecular Biology, Graduate School of Medical Science, Yamagata University, Yamagata, Japan
- Rajesh Honnutagi** Department of Medicine, Shri B.M. Patil Medical College, Hospital and Research Centre, BLDE Deemed to be University, Vijayapur, India
- Katsumi Iizuka** Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Gifu, Japan; Gifu University Hospital Center for Nutritional Support and Infection Control, Gifu, Japan
- SM Jeyakumar** Division of Lipid Biochemistry, National Institute of Nutrition, Indian Council of Medical Research, Hyderabad, India
- Karen R. Jonscher** Department of Anesthesiology, University of Colorado Denver, Aurora, CO, United States
- Rui Kang** Department of Surgery, University of Pittsburgh, Pittsburgh, PA, United States
- Vijay Kumar** Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India
- Narissara Lailerd** Department of Physiology, Chiang Mai University, Chiang Mai, Thailand
- Ji-Young Lee** Department of Nutritional Sciences, University of Connecticut, Storrs, CT, United States
- Yoojin Lee** Department of Nutritional Sciences, University of Connecticut, Storrs, CT, United States
- Gerhard Liebisch** Institute of Clinical Chemistry and Laboratory Medicine, University of Regensburg, Regensburg, Germany
- Rafael Longhi** Department of Basic Health Sciences, Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, Brazil
- Dewan Syed Abdul Majid** Department of Physiology, School of Medicine, Tulane University, New Orleans, LA, United States
- Dina Zakaria Mohamed** Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt
- Lata Mullur** Laboratory of Vascular Physiology and Medicine, Department of Physiology, Shri B.M. Patil Medical College, Hospital and Research Centre, BLDE Deemed to be University, Vijayapur, India
- Pablo Muriel** Laboratory of Experimental Hepatology, Department of Pharmacology, Cinvestav-IPN, Mexico City, Mexico
- Dong Thi Nham** School of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam
- Claudia Ojeda-Granados** Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, “Fray Antonio Alcalde”, Guadalajara, Mexico; Health Sciences Center, University of Guadalajara, Guadalajara, Mexico
- Princy Louis Palatty** Department of Pharmacology, Amrita Institute of Medical Sciences, Kochi, India
- Arturo Panduro** Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, “Fray Antonio Alcalde”, Guadalajara, Mexico; Health Sciences Center, University of Guadalajara, Guadalajara, Mexico
- Anita Pathil** Department of Internal Medicine IV, University of Heidelberg Hospital, Heidelberg, Germany
- Sladjan Pavlovic** University of Belgrade Institute for Biological Research “Sinisa Stankovic”, Belgrade, Serbia
- Snezana Pejic** University of Belgrade “Vinca” Institute of Nuclear Sciences, Belgrade, Serbia
- Pichapat Piamrojanaphat** Department of Biochemistry, Chiang Mai University, Chiang Mai, Thailand
- Arnadi Ramachandrayya Shivashankara** Undergraduate student, Father Muller Medical College, Mangalore, India
- Erika Ramos-Tovar** Laboratory of Experimental Hepatology, Department of Pharmacology, Cinvestav-IPN, Mexico City, Mexico
- Suresh Rao** Mangalore Institute of Oncology, Mangalore, India
- R. Chandramouli Reddy** Laboratory of Vascular Physiology and Medicine, Department of Physiology, Shri B.M. Patil Medical College, Hospital and Research Centre, BLDE Deemed to be University, Vijayapur, India
- Ingrid Rivera-Iñiguez** Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, “Fray Antonio Alcalde”, Guadalajara, Mexico; Health Sciences Center, University of Guadalajara, Guadalajara, Mexico
- José O. Rivera** School of Pharmacy-University of Texas at El Paso, El Paso, TX, United States
- Sonia Roman** Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, “Fray Antonio Alcalde”, Guadalajara, Mexico; Health Sciences Center, University of Guadalajara, Guadalajara, Mexico
- Sittiruk Roytrakul** National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathum Thani, Thailand

- Robert B. Rucker** Department of Nutrition, University of California, Davis, CA, United States
- Supicha Rungcharoenarrichit** Department of Biochemistry, Chiang Mai University, Chiang Mai, Thailand
- Samia Salim Sokar** Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt
- Maricruz Sepulveda-Villegas** Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, “Fray Antonio Alcalde”, Guadalajara, Mexico; Health Sciences Center, University of Guadalajara, Guadalajara, Mexico
- Farzad Shidfar** Department of Nutrition, School of Health, Iran University of Medical sciences, Tehran, Iran
- Surendra Kumar Shukla** Eppley Cancer Institute, University of Nebraska Medical Centre, Omaha, NE, United States
- Pejman Solaimani** Division of Gastroenterology and Hepatology, Department of Internal Medicine, VA Loma Linda Healthcare System, Loma Linda University, Loma Linda, CA, United States
- Wolfgang Stremmel** Department of Internal Medicine IV, University of Heidelberg Hospital, Heidelberg, Germany
- Daolin Tang** The Third Affiliated Hospital, Center for DAMP Biology, Key Laboratory of Protein Modification and Degradation of Guangdong Higher Education Institutes, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, People’s Republic of China; Department of Surgery, University of Pittsburgh, Pittsburgh, PA, United States
- K.R. Thilakchand** Department of Research, Mangalore Institute of Oncology, Mangalore, India
- Dang Kim Thu** School of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam
- Zoran Todorovic** University of Belgrade Faculty of Medicine, University Medical Center “Bezanijska kosa”, Belgrade, Serbia
- Chuong Tran** Division of Gastroenterology and Hepatology, Department of Internal Medicine, VA Loma Linda Healthcare System, Loma Linda University, Loma Linda, CA, United States
- Bansari J. Trivedi** Department of Nutrition Services, VA Loma Linda Healthcare System, Loma Linda, CA, United States
- Bui Thanh Tung** School of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam
- A Vajreswari** Division of Lipid Biochemistry, National Institute of Nutrition, Indian Council of Medical Research, Hyderabad, India
- Sunitha Venkatesh** Mangalore Institute of Oncology, Mangalore, India
- Yangchun Xie** Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China; Department of Surgery, University of Pittsburgh, Pittsburgh, PA, United States

This page intentionally left blank

Acknowledgments

The work of Dr. Watson's editorial assistant, Bethany L. Steven, in communicating with authors, editors, and working on the manuscripts was critical to the successful completion of the book. It is very much appreciated. Support for Ms. Stevens' and Dr. Watson's editing was graciously provided by Southwest Scientific Editing & Consulting, LLC. Direction and guidance from Elsevier staff was critical. Finally, the work of the librarian at the Arizona Health Science Library, Mari Stoddard, was vital and very helpful in identifying key researchers who participated in the book.

Heavy Metals and Low-Oxygen Microenvironment—Its Impact on Liver Metabolism and Dietary Supplementation

Kusal K. Das¹, Rajesh Honnutagi², Lata Mullur¹, R. Chandramouli Reddy¹, Swastika Das³, Dewan Syed Abdul Majid⁴, M.S. Biradar²

¹Laboratory of Vascular Physiology and Medicine, Department of Physiology, Shri B.M. Patil Medical College, Hospital and Research Centre, BLDE Deemed to be University, Vijayapur, India; ²Department of Medicine, Shri B.M. Patil Medical College, Hospital and Research Centre, BLDE Deemed to be University, Vijayapur, India; ³Department of Chemistry, BLDE Association's, Dr. P.G. Halakatti College of Engineering and Technology, Vijayapur, India; ⁴Department of Physiology, School of Medicine, Tulane University, New Orleans, LA, United States

1. INTRODUCTION

The **term heavy metal** refers to any metallic chemical element that has a relatively high density and is toxic or poisonous at low concentrations. The heavy metals constitute major fraction of the periodic table and are generally interpreted to include those metals from periodic table groups IIA through VIA. Examples of heavy metals are nickel, lead, mercury, cadmium, chromium, etc. Heavy metals cannot be degraded or destroyed. It enters in our bodies via food, drinking water, and air and primarily targets liver and other metabolically active tissues. As trace elements, some heavy metals (e.g., copper, selenium, zinc) are essential to maintain the metabolism of the human body. However, at higher concentrations they can lead to poisoning. Heavy metal poisoning may occur through various ways such as drinking water through lead pipe or occupational exposure (lead–cadmium or nickel–cadmium batteries) or stainless steel industries (nickel–chromium), refineries or petrochemicals (nickel, lead, cadmium), jewelry, etc.¹ Hypoxia belongs to the most serious factors that can directly impair the function of metabolic pathways in the animal cell. The exposure of experimental animals to hypoxia has been widely used in many morphological and physiological studies. Physiological hypoxia induces cell signaling process for the formation of new blood vessels (angiogenesis) to regulate vascular tone during developmental stage.² Physiological oxygen levels (PO₂) in healthy body varies from ~100 Torr in the alveoli to <10 Torr in medulla of kidney and retina.³ Tissue exposure to low-oxygen tension is observed in several physiological and pathological conditions such as ischemia for shorter duration or in case of the high-altitude inhabitants or any other chronic diseases for longer duration of hypoxic exposure. In both cases, hypoxic cells are programmed to rapid adjustment to maintain O₂ supply to most vital organs such as heart and brain. It is understood that atherosclerosis, stroke, or vascular occlusion leads to tissue ischemia followed by hypoxia. Tissue hypoxia also develops through immune cell infiltration in vascular dysfunction during chronic inflammation process.^{3,4} It has been observed that hypoxia absurdly stimulates free radicals release from the mitochondria that control the transcriptional and posttranslational response to low-oxygen conditions.^{5,6} Hypoxia-induced generation of reactive oxygen species (ROS) has been a subject of theoretical and practical dispute as experimental designs able to quantitatively evaluate ROS formation. Under normoxic conditions, ROS (constantly generated in erythrocytes) are mostly counteracted by their endogenous (superoxide dismutase, glutathione peroxidase, catalase or reduced glutathione) or exogenous (vitamin C, vitamin E, etc.) antioxidant defense systems. Studies also show that wild-type human hepatoma cells (Hep3B) increase ROS generation of metal-activated cell signaling pathways during hypoxia.^{5,6} Valko M et al.⁷ stated that “hypoxia-activated gene transcription via a mitochondria-dependent signaling process induces increased ROS.” The mechanisms by which mammalian cells adapt to acute and chronic alterations of oxygen tension are extremely important to understand the exact homeostasis regulation to counteract hypoxia-induced cell damage as a therapeutic strategy. Heavy metals are capable to induce expression of HIF-1 transcriptional factor and vascular endothelial growth factor (VEGF) genes through the

phosphatidylinositol 3-kinase or Akt pathway or ROS.⁸ Heavy metals–induced alteration of the hypoxia signaling system influenced by metal-induced oxidative stresses are responsible for progression of metastasis.⁹ This chapter gives a brief understanding of current state of knowledge of chronic hypoxia and its influence on generation of ROS by inducing oxidative stress in the physiological system. The review will also provide recent update of heavy metal nickel toxicities on oxidant and antioxidant balance and molecular interaction of chronic hypoxia and heavy metal nickel (Ni) in the physiological system in vivo. Cellular hypoxia causes an initiation of hypoxia-response genes responsible for angiogenesis, oxygen transport, and metabolism.¹⁰ Chronic hypoxia stimulates NF- κ B gene expressions and it reduces KLF4, which further leads to an enhanced NOS2 expression (Fig. 26.1). **Both hypoxia and heavy metal exposure induce generation of ROS and increase expression of p53, NF- κ B, AP-1, MAPK, and HIF-1 α . The increase expression of all these transcription factors leads to either cellular adaptation or cell death.**¹¹ It is also to be mentioned that hypoxic injury due to metal assault or hypoxia exposure causes “cell death” by cells swelling, plasma and nuclear membrane disruption, cellular lysis in association with acute inflammation that may exacerbate the initial hypoxic injury response. However, the alternative mode of cell death, apoptosis, is also possible (Fig. 26.1). During apoptosis, the cells use their molecular machinery to shrink or expand into membrane-bound apoptotic bodies, with or without nuclear fragments that are easily phagocytosed by adjacent tissue cells or macrophages and minimize any acute inflammatory response.

Liver is an important metabolically active organ. It stores additional nutrients in the form of glycogen and lipids. During the need of the hour these nutrients yield energy and keep all the vital functions intact. Hepatocytes also synthesize plenty of proteins including albumin and clotting factors. Furthermore, it synthesizes cholesterol and triglycerides. Another important function of liver is to produce bile salts which are essential for digestion and absorption of lipids. The hepatocytes also play an important role as the center of detoxification in the body, influencing drug metabolism and breakdown of hormones. This organ is an important source of storage of vitamins such as B12, A, D, K and folic acid, besides being an important source of iron. To make the liver a well-functioned organ, a considerable amount of oxygen is needed. Altered metabolic functions due to toxic insults or metabolic stress due to hypoxia or heavy metal toxicities disturb oxygen homeostasis in liver and lead to serious liver diseases. Most of the cases, malfunction of liver leads to fatty liver symptoms and the cell signaling pathways greatly affected is oxygen dependent, hence hypoxia may be considered as an important cause of liver malfunction.¹² Interestingly, hypoxia and divalent heavy metals such as nickel (Ni) and lead (Pb) generate ROS and disturbed oxidant/antioxidant balance which is linked to the transcriptional factor HIF-1 α . The results from the author’s laboratory showed both divalent cationic heavy metal (Ni and Pb) and chronic sustained hypoxia stimulate the production of HIF-1 α transcription factor and VEGF gene expression in metabolically active tissues in similar molecular mechanism. Heavy metals cause oxidative stress by inducing the generation of ROS; reducing the antioxidant defense system of cells via depleting glutathione; interfering with some essential metal; inhibiting sulfhydryl (SH), dependent enzyme, or antioxidant enzymes activities; and/or increasing susceptibility of cells to oxidative attack by altering membrane integrity and fatty acid composition.^{13,14}

Nutrients such as vitamin C or E are found to be the most effective circulatory antioxidant in human system.¹⁵ Ascorbic acid or vitamin C prevents lipid peroxidation, oxidation of low-density lipoproteins, and advanced oxidation protein products.¹⁶ Vitamin C may comprise the first line of defense system in RTLF against external pro-oxidative assaults.¹⁷ It has been reported that intracellular depletion of ascorbic acid aggravated some heavy metal (nickel, cobalt, etc.)-induced carcinogenicity and acute toxicity.¹⁸ The effect of simultaneously supplemented vitamin C on experimental nickel treatment




FIGURE 26.1 Graphic representation showing heavy metals or hypoxia-induced common cellular abnormalities. *NF- κ B*, nuclear factor-kappa B; *NO*, nitric oxide; *NOS*, nitric oxide synthase; *ONOO⁻*, peroxynitrate; *HIF-1 α* , hypoxia inducible factor 1 α ; *ROS*, reactive oxygen species; *VEGF*, vascular endothelial growth factor.

shows ascorbic acid is capable to reduce intestinal absorption of nickel. The mechanism involves that vitamin C is capable to reduce ferric iron to ferrous iron in the duodenum, thus availability of divalent ferrous ion increases which competes with nickel or lead also as divalent cation for intestinal absorption.¹⁹ Recent reports indicate the capability of ascorbic acid as a regulatory factor may influence gene expression, apoptosis, and other cellular functions of living system exposed to heavy metals.²⁰ This chapter elaborately explains the role of dietary supplementation of nutrients such as vitamins and other nutrients in heavy metals such as nickel and lead, which induces altered hepatic functions in low-oxygen microenvironments.

2. HEAVY METALS AND ITS INTERACTIONS

Heavy metals interact with the biological system in a complex manner. Even elemental speciation of the metals also matters in its interactions with systems. The **term heavy metal** refers to any metallic chemical element that has a relatively high density and is toxic or poisonous at low concentrations. The heavy metals constitute major fraction of the periodic table and are generally interpreted to include those metals from periodic table groups IIA through VIA. Examples of heavy metals are nickel, lead, mercury, cadmium, chromium, etc.¹

2.1 Heavy Metal Toxicities: Nickel and Lead

There are five priority substances which are selected by WHO for the nickel risk assessment. They are nickel powder, nickel sulfate, nickel chloride, nickel carbonate, and nickel nitrate. Nickel powder (T; R48-23) has been classified in chronic toxicity classification as per environmental risk assessment report on nickel. NiSO_4 , NiCl_2 , NiCO_3 , and NiNO_3 are classified as carcinogen class I (by inhalation), reproductive toxicants class II (may cause harm to unborn children), and chronic toxicants (T; R48-23). If particle size of nickel powder found to be less than 0.1 μm , it is classified as T; R52-53 (harmful to the aquatic environment).²¹ Acute toxicity in humans, which results from absorption through the gastrointestinal tract or by inhalation through lungs, was first reported by Sunderman in 1954.²² Further studies showed that a single dose oral LD50 in rats for the less-soluble nickel oxide and subsulfide was $>3600 \text{ mg Ni/kg bwt}$, whereas the oral LD50 for the more soluble nickel sulfate and nickel acetate ranged from 39 to 141 $\text{mg Ni kg}^{-1} \text{ bwt}$ in rats and mice.²³ The metal is not only an allergen but also a potential immunomodulatory and immunotoxic agent in humans.¹⁹ Weischer et al.²⁴ reported that oral administration of nickel as NiCl_2 in male rats over a period of 28 days at concentration of 2.5, 5.0, and 10.0 $\mu\text{g/mL}$ in drinking water (0.38, 0.75, or 1.5 mg/kg day) resulted in significant dose-dependent hyperglycemia, decrease in serum urea, and significant increase in urine urea. At 0.75 mg/kg doses, increased leukocyte count was also observed. It was noticed that exposure of dietary nickel sulfate hexahydrate (100, 1000, or 2500 ppm) to dogs for 2 years failed to produce significant signs of compound-related toxicity.²⁵ The toxicity of the different nickel compounds is related to its solubility, with soluble nickel sulfate being the most toxic and insoluble nickel oxide being the least toxic. The difference in the toxicity across compounds is probably due to the ability of water-soluble nickel compounds to cross the cell membrane and interact with cytoplasmic proteins.²¹

Lead poisoning can affect almost all parts of the body, but its effects are most pronounced on the central nervous system and kidneys. Lead can impair cognitive development, which can lead to learning disabilities and behavioral problems. Acute lead exposure can cause encephalopathy, severe abdominal pain, vomiting, diarrhea, coma, seizures, and, in some cases, death. Chronic exposure can cause weakness, prolonged abdominal pain, anemia, nausea, weight loss, fatigue, headache, and loss of cognitive function. Chronic, low-level lead exposure can be asymptomatic until kidney function starts to deteriorate.¹¹ Lead has no known physiologically relevant role in the body, and its harmful effects are myriad. Lead and other heavy metals create reactive radicals, which damage cell structures including DNA and cell membranes. Lead also interferes with DNA transcription enzymes that help in the synthesis of vitamin D, and enzymes that maintain the integrity of the cell membrane. Anemia may result when the cell membranes of red blood cells become more fragile as the result of damage to their membranes. Lead interferes with metabolism of bones and teeth and alters the permeability of blood vessels and collagen synthesis. Lead may also be harmful to the developing immune system, causing production of excessive inflammatory proteins; this mechanism may mean that lead exposure is a risk factor for asthma in children. Lead exposure has also been associated with a decrease in activity of immune cells such as polymorphonuclear leukocytes. Lead also interferes with the normal metabolism of calcium in cells and causes it to build up within them. It is metabolized by CYP450 to trimethyl lead (TML). Mechanisms of its toxicity include damage to membranes, disturbances in energy metabolism, and direct interference with neurotransmitter synthesis. Symptoms of its toxicity include nausea, vomiting, diarrhea associated with nervous system problems such as irritability, headache, and restlessness. Chronic heavy sniffing of leaded gasoline results in signs of dementia and encephalopathy, with cerebellar and corticospinal symptoms. Lead primarily acts by competing with endogenous cations on protein-binding sites. In particular, lead can substitute both calcium and zinc in

numerous proteins. Among stress-response genes that were upregulated by lead treatment, GFAP, microsomal glutathione S-transferase, mitochondrial 10KDa heat shock protein, and HSP70 are all involved in general cellular responses to stress. *Daphnia* hemoglobin gene was greatly expressed following lead exposure.²⁶

3. HYPOXIA PATHOPHYSIOLOGY

Hypoxia is a pathological condition in which the body as a whole (generalized hypoxia) or a region of the body (tissue hypoxia) is deprived of adequate oxygen supply. Variations in arterial oxygen concentrations can be part of the normal physiology, for example, during strenuous physical exercise. In healthy humans, there is a range of physiological oxygen levels within the tissues of the body, ranging from PO₂ values of –100 Torr in the alveoli of the lungs to less than 10 Torr in tissues such as the medulla of the kidney and the retina.²⁷

3.1 Hypoxia Microenvironment

Physiological hypoxia is an important microenvironmental signal in a range of processes including new blood vessel formation (angiogenesis) during development and wound healing, the regulation of vascular tone, and the response to exercise. However, tissue hypoxia is also associated with a diverse and wide range of pathophysiological processes including (but not limited to) vascular disease, chronic inflammation, and cancer.² In vascular diseases such as atherosclerosis and stroke, vascular occlusion leads to acute or chronic tissue ischemia with resultant hypoxia. In chronic inflammatory diseases, the greatly increased metabolism of inflamed tissue due to immune cell infiltration matched with vascular dysfunction leads to tissue hypoxia.²⁷ Hypoxia results from conditions such as ischemia, hemorrhage, stroke, premature birth, and other cardiovascular difficulties. Among which hemorrhagic shock is the leading cause of death and complications in combat casualties and civilian settings. It has been shown to cause systemic inflammation response syndrome, multiple organ dysfunctions, and multiple organ failure.²⁸ Hypoxia has been shown to lead to increases in intracellular free calcium concentration (Ca²⁺), 5-lipoxygenase, lipid peroxidation, cyclooxygenase (COX), constitutive nitric oxide synthase (cNOS), leukotriene B₄ (LTB₄), prostaglandin E₂ (PGE₂), interleukins, tumor necrosis factor- α (TNF- α), caspases, complement activation, kruppel-like factor 6 (KLF6), inducible nitric oxide synthase (iNOS), heat shock protein 70kDa (HSP-70), and hypoxia-inducible factor-1 α (HIF-1 α). The sequence of their occurrence provides the useful information for studying the mechanisms underlying the hypoxia-induced injury as well as therapeutic targets to prevent or ameliorate the injury.¹¹ Hypoxia, or inadequate oxygenation, causes various responses within the body. Its effects are usually mediated via the activation of HIF-1. HIF-1 activation can lead to upregulation of various genes such as erythropoietin and growth factors that help tissues adjust to the decreasing oxygen availability. Semenza and Wang defined a binding site critical for the hypoxia-inducible function, which involves a transcription factor induced by hypoxia. Subsequently, they purified a DNA-binding complex bound to the HRE by affinity purification using oligonucleotide with the HRE sequence and thus identified the encoding cDNAs.²⁹

3.2 Hypoxia and Heavy Metals (Nickel and Lead)

Over the recent years, induction of signaling pathways that regulate key cellular responses related to cancer growth and progression by metals has been the focus of many studies. The unraveling of these pathways and the deciphering of their interplay with metals should allow a better understanding of metal toxicity and hopefully will enable development of prophylactic strategies and therapeutic approaches. Authors' laboratory and works of Leonard (2004) have shown the mechanisms of toxicities caused by heavy metals such as nickel and lead, emphasizing on the involvement of the hypoxia signaling pathway by metal-induced generation of ROS and oxidative stress generation.^{20,30} Hypoxia-induced factor HIF-1 controls precise oxygen homeostasis by modulating expression of several cancer-related genes, including heme oxygenase 1 and vascular endothelial growth factor. The carcinogenic metals such as nickel, lead (Pb), or chromium have been known to activate HIF-1.^{8,31} It has been observed that heavy metal-induced ROS generation during the exposure of cells to metals mimic hypoxia-like symptoms.³² The mechanisms of carcinogenesis caused by heavy metals such as nickel emphasizes on the involvement of the hypoxia signaling pathway by metal-induced generation of ROS and oxidative stress generation in cancer progression.⁹ One of the pathways by which heavy metals such as nickel and lead induce intracellular hypoxia is by reducing heme biosynthesis. Low level of heme reduces intracellular oxygen tension and simply intracellular low Fe²⁺ and low oxygen tension inhibit PHD₂ (prolyl hydroxylases). Under normoxic conditions, HIF-1-prolyl hydroxylases (PHD) hydroxylate the prolyl residues at amino acids 402 and 564. These enzymes require dioxygen, Fe²⁺, ascorbate, and two oxoglutarates for activity. The hydroxylated peptides interact with an E3 ubiquitin-protein ligase complex composed of

pVHL (von Hippel–Lindau tumor suppressor protein), elongin B and C, and Cullin 2 (CUL2), and then poly-ubiquitinated, resulting in HIF-1 α degradation by the 26S proteasome. Under hypoxic conditions, HIF-1 α is not hydroxylated because the major substrate, dioxygen, is not available. The unmodified protein escapes the VHL-binding, ubiquitination, and degradation, and then dimerizes HIF-1 α and stimulates the transcription of its target genes.³³

4. HEAVY METALS IN LIVER DISEASES

Heavy metals related to cardiovascular and pulmonary disorders are quite common and reported elsewhere, but currently, heavy metals and its impact on liver disease are considered as serious as before.³⁴

4.1 Heavy Metals and Liver Pathophysiology (Nickel and Lead)

Fatty liver disease is considered as one of the important causes of chronic liver disease, and it is manifested by a complicated etiology. Heavy metal-induced changes in liver pathophysiology including fatty liver changes are under non-alcoholic fatty liver disease (NAFLD) category. Fatty liver induces a prolonged inflammatory response which leads to fat accumulation in the liver due to hepatocellular damages. One study showed that heavy metals caused NAFLD in men under 24 BMI. In case of overweight and obese, it becomes more serious. It was also observed that lead (Pb) causes more liver damage than nickel (Ni).³⁵ Heavy metals such as nickel and lead cause hepatocellular hyperplasia, which may lead to even carcinoma of liver. Studies on nickel clearly showed elevation of liver aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltranspeptidase.^{6,36} Furthermore, it has been found that at advanced stages of hepatic cirrhosis, there was a significant increase of hepatic levels of nickel.³⁷ Another study also showed lower serum nickel concentration in liver cirrhosis patients which attributes a possible reduction of hepatic synthesis of nickel transport protein, i.e., nickeloplasmin and albumin.³⁸ Similarly, study also showed that lead and mercury are linked with NAFLD.³⁹ Furthermore, it was observed that lead (Pb) become conjugated in liver and stored there in highest concentration. Lead exposure on experimental animal showed an elevation of AST, ALT, and alkaline phosphatase, which clearly indicate a possible liver failure.⁴⁰ The most common pathways for metal-induced hepatotoxicity is through free radicals due to oxidative stress. The free radicals which are generated due to heavy metal exposure damage cell membrane lipid bilayers, nucleic acids, and enzymes. These in turn causes functional impairment of cell integrity and disturbs cytoprotective systems. Furthermore, it imparts oxidant and antioxidant imbalances and leads to cellular injuries. The mechanisms of hepatotoxicities are through affecting hepatic mitochondrial respiratory systems by reducing cytochrome *c* oxidase activity. Excessive accumulation of heavy metals also disturb hepatic calcium regulatory system by damaging microsomal calcium sequestration and damaging hepatocellular DNA, which further leads to carcinoma of liver.⁴¹

4.1.1 Nickel and Hepatotoxicities

A transient increase in serum bilirubin was observed in 3 out of 10 workers who were hospitalized after drinking water from a water fountain, contaminated with nickel sulfate.⁴¹ In rats, decreased liver weight was observed following exposure for 28 days to 2 year to 0.97–75 mg/kg day of nickel chloride or nickel sulfate.⁴² Recent studies on rats by Das et al.⁴³ revealed a nickel sulfate-induced degenerative effect on hepatic tissue. They have observed that after the intraperitoneal injection of nickel sulfate, normal hepatic architecture was greatly altered, along with appearance of vacuolated cytoplasm (fatty liver), eccentric nuclei, and Kupffer cell hypertrophy. One report described decreased hepatic and renal transaminase activities after nickel treatment in rats, which was found more deleterious in a protein-restricted dietary regimen.⁴⁴ Nickel sulfate also decreases the liver ascorbic acid and cholesterol levels in rats.⁶ Misra and coworkers showed that a single intraperitoneal injection of nickel (II) acetate increased lipid peroxidation and glutathione-S-transferase activity in rat liver and kidney while concomitantly decreasing the glutathione concentration and glutathione reductase activity.⁴⁵ The same group found that the nickel-induced hepatic lipid peroxidation in different strains of mice was concurrent with nickel's effect on antioxidant defense systems in liver and kidney.⁴⁶ The magnitude of nickel-induced lipid peroxidation showed a reverse correlation with the extent and direction of its effect on glutathione and glutathione peroxidase glutathione reductase but not on CAT, SOD, or glutathione-S-transferase.⁴⁶ Das et al.⁴⁷ showed, after the nickel treatment of rats, a significant rise in hepatic lipid peroxides and a decrease in antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) activities and in the hepatic glutathione concentration. The alteration of oxidant and antioxidant balance due to hepatic lipid peroxidation indicates an elevation of enzyme phospholipase activities while peroxidic disintegration of various subcellular organelles and membrane lipid layers with nickel exposure. Furthermore, it may be postulated that nickel causes Kupffer cell hyperactivity through inflammatory cytotoxic mediators along with fatty liver changes and




FIGURE 26.2 Normal (A) and nickel sulfate (B)-treated rat liver histopathology (45 \times).

eccentric nuclei in hepatocellular architecture. Nickel-induced changes of hepatic SOD, CAT, and GSH-Px reveal possible interaction of free radicals and hepatic enzymes and damaging SH protective mechanism against lipid peroxidation.⁴⁷ Study also revealed that nickel or some other heavy metals cause alteration in hepatic HMG-CoA reductase activities and disturb LDL-receptor gene expression. It ultimately changes the lipid profile of physiological system.^{48,49} Another study showed that nickel induced severe liver damage as indicated by rise of SGOT, SGPT, and ascorbate-cholesterol metabolism in experimental rats. The study also showed that nickel sulfate causes decrease in absolute liver weight without altering hepatosomatic index which is indicative of hepatic degenerative changes.⁵⁰ Increased activity of SGOT and SGPT after nickel exposure reflects possible leakage of hepatic enzymes from liver cytosol in circulatory system due to nickel-induced cellular damages.⁵¹ Another observation on nickel-induced hyperglycemia in experimental animals indicates a marked reduction in hepatic fructose-2-6-bisphosphate, which is an indicator of gluconeogenic and glycolytic pathways suggestive of increase of liver gluconeogenesis.⁵²

In histopathological studies in the author's laboratory, the liver showed congestion of central veins and sinusoids and some hepatocytes suffered from vacuolar degeneration, fatty changes, etc. (Fig. 26.2A and B). Mathur et al. also observed the same in nickel sulfate-treated rats.⁵³ Results from the author's laboratory are in agreement with those obtained by El-Saeed and Mekawy⁵⁴, Ptashynski and Klaverkamp,⁵⁵ and Sobecka⁵⁶. Nickel intoxication causes a vacuolization of the cytoplasm, the increase in numbers of pyknotic nuclei, and the decrease in glycogen content in hepatocytes.⁵⁷ The hydropic degeneration of hepatocytes may be due to the irritation of toxic metabolites and impairment of potassium sodium pump that disturbs the ion exchange through the cell wall. The increased oxidative stress, the formation of ROS as well as depletion of cellular antioxidant level may be resulted in histopathological changes of liver. Heavy metal-induced interstitial fibrosis, increased numbers of pyknotic nuclei, as well as necrosis in hepatocytes have also been reported earlier.⁵⁸

4.1.2 Lead and Hepatotoxicities

Like nickel, lead too raises serum LDL-cholesterol, VLDL-cholesterol, total cholesterol and triglycerides, and decreases serum HDL-cholesterol and HDL/LDL ratio. It may be due to changes of the gene expression of hepatic enzymes and LDL receptor synthesis. Defects in the LDL-receptor interfere with cholesterol uptake from the bloodstream, which in turn causes excess cholesterol synthesis in the liver and high levels of serum total cholesterol and LDL-cholesterol.⁴⁸ The improvement of serum lipid profile also reflects normalization of liver P450 enzyme system function by α -tocopherol.⁵⁹ Lead generates long-lived ROS. These might cause oxidative stress that results in oxidative deterioration of biological macromolecules leading to oxidative damage to the hepatic cells.⁶⁰ In an experimental study, lead acetate induced increase plasma MDA with decreased hepatic SOD, CAR, and GSH-Px were noticed which are indicative of hepatic oxidative stress.⁶¹ During hepatotoxicity, these enzymes are structurally and functionally impaired by free radicals, resulting in liver damage. Glutathione comprises up to 90% of the nonprotein thiol content of mammalian cells and performs a pivotal role in maintaining their metabolic and transport functions. It acts as a nucleophilic "scavenger" of many compounds and their metabolites via enzymatic and chemical mechanisms, converting electrophilic centers to ether bonds. Glutathione depletion to about 20%–30% of total glutathione levels can impair cell defenses against toxic actions, which may lead to cell injury




FIGURE 26.3 Normal (A) and lead acetate– (B) treated rat liver histopathology (45×).

and death.²¹ Furthermore, glutathione is considered a crucial factor in maintaining the structural integrity of cell membranes, largely through reactions that protect the membrane against free radical formation.⁶² Lead interacts with negatively charged phospholipids in membranes and through the induction of changes in membrane physical properties could facilitate the propagation of lipid oxidation in liver. Lead affects membrane-related processes such as the activity of membrane enzymes, endo- and exocytosis, transport of solutes across the bilayer, and signal transduction processes in hepatocytes by causing lateral phase separation.^{30,61} Lead-induced oxidative stress in liver caused increase of rate of production of hydroxyl radicals which may lead to lysosomal and mitochondrial damages. Besides these direct hepatocellular damaging by lead-induced ROS and reactive nitrogen species (RNS), it may also interfere cell signal transduction by reversible oxidation and nitrosation of protein SHs in the hepatic sinusoid.⁶³

Histopathological studies of lead-treated rat liver from the author's laboratory indicated little swollen hepatocytes with ill-defined cell borders with variation in cellular size and shape. The nuclei are large, more vesicular with variable size and shape, and contain multiple three to four prominent nucleoli. The cytoplasm is vacuolated and microvesicular. There are foci of fatty change and ballooning degeneration and necrosis of hepatocytes in zone 3 (centrilobular) areas.

The portal area appears mildly enlarged with mild proliferation fibrous tissue with infiltration of mixed acute and chronic inflammatory cells. The sinusoidal spaces are variably widened with increase in number of Kupffer cells. Central vein shows features of dilatation and congestion (Fig. 26.3B). Results clearly indicate hepatocellular damage by lead exposure.

4.2 Possible Mechanism of Altered Hepatocellular Architecture by Heavy Metals

It was found that most of the divalent heavy metals such as nickel, lead, and cadmium enter into systemic circulation from intestine through metal transporter proteins (MTP 1). Through circulation these metals enter first to liver via portal circulation where it is absorbed through sinusoidal capillaries. In hepatocytes, these heavy metals are penetrated through specific membrane transporters such as DMT1, ZIP8, and ZIP14t.^{64,65}

Heavy metals such as nickel or lead accumulate in liver and resulting hepatocellular damages induce infiltration of polymorphonuclear neutrophils. This in turn causes activation of Kupffer cells followed by necrosis. Usually heavy metal-activated Kupffer cells secretes several inflammatory cytokines and causes secondary liver damage.⁶⁶ The exact mechanism of hepatocellular damages by Kupffer cells is yet to be cleared, but a possible role of free radicals, nitric oxide, tumor necrosis factor α (TNF- α) cannot be ruled out⁶⁷ (Fig. 26.4). Studies on nickel showed hepatic apoptosis due to overexpressions of caspase-3, caspase-9, and PARP mRNA.⁶⁸

5. HYPOXIA AND LIVER DISEASES

Liver pathophysiology is oxygen dependent. As it is an important organ for metabolism, it is always in demand for oxygen. Hepatic artery, portal veins, and central veins play the pivotal role to maintain liver oxygen homeostasis.⁶⁹ It was found that liver always make oxygen microenvironment differentially than other organs. The important change




FIGURE 26.4 Heavy metal–induced liver malfunctions.

in hypoxia-induced hepatocellular architecture is the formation of plasma membrane protrusion. This formation has numerous cytosol and endoplasmic reticulum. It ultimately causes swelling of mitochondria and near 30%–50% increase of cell volume. These changes can be reversed if reoxygenation to hepatocytes occurs. The hepatocytes may be permanently injured if hypoxia sustains, and it will lead to complete damage of plasma membrane transport system which will cause release of intracellular ingredients of hepatocytes.⁷⁰ Oxygen tension in periportal and perivenous part of liver is 60–75 mmHg and 30–35 mmHg, respectively, which clearly indicates a persistent hypoxia in liver due to high metabolic functions.⁶⁹ Study reveals that hypoxia is linked to several types of liver diseases. The mechanism by which hypoxia is able to change liver pathophysiology is mainly through HIF-1 and NOS2 expressions. Both these factors are involved in hepatocytes, Kupffer cells, and immune cells. Hypoxia in liver increases the level of TNF- α , IL-1 from hepatocytes which further promote ROS. These ROS in liver are found to have decreased glutathione levels and elevated oxidized glutathione.⁷¹ Although a direct hypoxia response to liver was not found in healthy individuals, in the case of viral hepatitis, metabolic diseases, steatohepatitis, and cancer, an elevation of HIFs is noticed. It has been observed that HIFs induce pathogenesis of hepatocellular carcinoma, and both HIF-1 α and VEGF levels were increased in hepatocellular carcinoma.⁷² Many chronic liver diseases due to vital infection, metabolic disorders, or alcoholism are found to be connected with HIFs.⁷³ Actually HIFs act as protective agents from liver injuries due to hypoxia. HIFs induce generation of VEGF, adenosine, nitric oxide, and Akt signaling pathways to prevent hepatocellular injuries from hypoxia.^{74,75} It is observed that Dec1 expression increases in alcoholic liver which indicates HIF-1 α regulatory gene involvements to protect liver of alcohol toxicities. Hypoxia region of liver shows alteration of parenchymal vasculature, which leads to fibrosis.⁷⁶ HIF-1 α expression stimulates hepatic stellate cells (HSCs) and fibroblasts. Another study on NAFLD phenotype showed hypoxia accelerated the NAFLD phenotype with higher level of lipogenesis and inflammation.⁷⁷ Another important phenomenon of hypoxia-induced liver injury is through ATP depletion during hepatic ischemia which also leads to necrotic cell death. Hypoxic liver enhances glycolytic metabolism and prevents its best against hypoxia injuries. In case of low glycogen in liver, hypoxia leads to rapid cellular ATP depletion and necrosis.⁷⁸ Hypoxia-exposed liver also shows alteration of pH microenvironment. Hypoxia leads to acidosis in liver, which prevents necrotic cell death in liver in spite of low ATP levels.⁷⁹

5.1 Hypoxia—Liver Histopathology

In histopathological studies in the author's laboratory, the subchronic hypoxia–exposed rat liver showed endothelial cells surrounded by a ring of collagen fibers in the central vein. The sinusoids are lined by both endothelial cells and Kupffer cells both of which have inconspicuous flattened nuclei and ill-defined cytoplasmic margins. The hepatocytes are polygonal in shape with well-defined borders and appear to be little swollen with mild narrowing of the sinusoidal spaces. The nucleus is single, is round, and has a fine chromatin pattern with one to two clearly defined amphophilic prominent nucleoli. More or less it reflects normal architecture with insignificant changes in hypoxia-exposed rat liver (Fig. 26.5B).




FIGURE 26.5 Normal (A) and chronic hypoxia- (B) exposed rat liver histopathology (45 \times).




FIGURE 26.6 Hypoxia exposed with nickel sulfate- (A) and lead acetate- (B) treated rat liver histopathology (45 \times).

5.2 Hypoxia and Heavy Metals (Nickel and Lead)—Liver Histopathology

There is evidence of fatty change and ballooning degeneration and necrosis of hepatocytes. The portal area appears enlarged with severe proliferation fibrous tissue with infiltration of mixed acute and chronic inflammatory cells in nickel sulfate-treated subchronic hypoxia-exposed rats (Fig. 26.6A). In the case of subchronic hypoxia-exposed lead acetate-treated rats, distorted “lobular” architecture of liver parenchyma is noticed. Hepatocytes appear to be little swollen and cytoplasm is vacuolated, microvesicular, and eosinophilic (Fig. 26.6B). It also shows increase in number of mitotic figures along with foci of fatty change and ballooning degeneration and necrosis of hepatocytes in zone 3 (centrilobular) areas. Moderate proliferation of a portal area with fibrous tissue with infiltration of mixed acute and chronic inflammatory cells and variable widening of sinusoidal spaces along with Kupffer cell hyperplasia, dilatation, and congestion of central vein are also observed.

6. HEAVY METALS (NICKEL AND LEAD), HYPOXIA, AND LIVER FUNCTIONS—ROLE OF DIETARY SUPPLEMENTATIONS

Dietary supplementation of protein and other antioxidants including chelators are found to be effective against metal-induced hepatotoxicities. It has been found that metal ions interact with protein in a coordinated manner and chelate. These protein chelator compounds change the toxic characteristics of heavy metals by degrading it. The mode of hepatotoxicities by toxic metals such as nickel and lead are similar with hypoxia exposure. The cell signal pathways of nickel or lead and hypoxia

usually take place through HIF-1 α expressions and further manifestation of expression of hepatic VEGF and NOS2. Both nickel or lead and hypoxia exposure induce ROS and inflammatory cytokines and damages hepatocytes, and interestingly, dietary supplementation of antioxidants such as vitamins C or E and high proteins combat the toxicities from these exposures.

6.1 Heavy Metals, Liver Functions, and Dietary Supplementation

The most common therapeutic way to combat heavy metal toxicity is chelation therapy which leads to metal excretion, but chelators themselves have many contraindications. Chelators such as EDTA and meso-2,3-dimercaptosuccinic acid (DMSA) are routinely used against Pb poisoning, but no such chelators are found to detoxify nickel poisoning so far. Hence alternative therapy, especially dietary supplementation, is now gaining momentum against heavy metal poisoning. As per WHO and the US Dietary Supplements Health and Education Act (DSHEA) of 1994, vitamins, minerals, herbs, amino acids, or other food substances additionally supplemented in diets are considered as dietary supplementation.⁸⁰ Most of the cases these dietary supplementations are found to be safe for health.⁸¹ Some studies showed that Zn or Se are protective against Pb and Ni toxicity in liver, kidney, and brain. These micronutrients facilitate antioxidant defense mechanisms of metabolically active tissues including liver by acting as cofactor for synthesis of glutathione peroxidase (GSH-Px).⁸² One interesting observation is the beneficial role of iron supplementation in metal exposure. In presence of dietary supplemented iron, it competes with other divalent cations derived from metals such as Ni, Cd, or lead at the level of its transporter proteins such as divalent metal transporter-1 (DMT1) and metal transporter protein 1 (MTP1) in the intestine and reduced uptake of these heavy metals.⁸³ Dietary supplementations of some elements such as calcium or magnesium are also found to be effective against Pb or Ni toxicity. The elements usually decrease heavy metal absorption from intestine or competitively binds with active sites of intracellular metal-binding protein in hepatic tissues and prevent heavy metals such as nickel, cadmium, and lead to exert hepatic tissue damages.^{84,85} Some dietary supplementations such as *Allium sativum* Linn (garlic) were found to be hepatoprotective against heavy metals such as nickel and chromium VI.⁸⁶ Garlic has been found to be effective against heavy metal toxicities in liver through a number of mechanisms, such as scavenging radicals, increasing glutathione levels, increasing the activities of enzymes such as glutathione S-transferase and catalase, and inhibiting cytochrome p4502E1. Studies of Vimal and Devaki⁸⁷ showed that allicin (diallyl thiosulfinate) which is the main biological active compound derived from crushed garlic is highly protective against Cr VI- or lead-induced hepatic lipid peroxidation. Garlic also contains a number of amino acids that are required for the formation of an enzymatic antidote to free radical pathology, which is created by various pollutants including heavy metals. Cysteine, glutamine, isoleucine, and methionine found in garlic help to protect the liver cells from such free radical damage.^{88,89} Raw garlic extract can effectively protect the body from metal toxicity. Garlic contains the highest level of the antioxidant selenium, which affords excellent hepatocellular protection.⁸⁹ Vitamin supplementations in diet are extremely popular against heavy metal toxicities as low concentration of vitamins C, B1 and B6 are found to have increased sensitivity toward Cd, Ni, and Pb toxicity in hepatic tissues.⁹⁰ It is further observed that vitamins C and E are natural exogenous nonenzymatic antioxidants which prevent liver from oxidative stress by preventing hepatic lipid peroxidation.⁴⁷ Besides antioxidant actions, vitamin C also acts as a chelating agent like EDTA against Pb toxicities in hepatic tissues.⁹¹ Experimental study in rats has shown a beneficial effect of vitamin E pretreatment against heavy metals induced an alteration in liver antioxidant defense mechanisms.^{20,92} Supplementation of vitamins B1 and B6 were found to be effective in decreasing Pb concentration in liver by reversing ALAD activity. Vitamin B1 facilitates Pb excretion and reduces the Pb toxicity.⁹³ Other good hepatoprotective agents against heavy metal toxicity are black tea or green tea, grapes, and tomatoes. The bioactive constituent of these edibles are mainly catechins, flavonoids, and polyphenols. These compounds are antioxidants by nature and act as chelators against Pb-, Ni-, or Cd-induced hepatotoxicity.^{94–96} Some other plants such as liquorice (*Glycyrrhizae radix*) and ginseng (*Panax ginseng* Meyer) are also found to be effective against Cd-, nickel-, and Pb-induced hepatotoxicities. These plants are routinely used in diet by Chinese, Malaysians, and Africans.^{97,98} Currently, some probiotics such as *Lactobacillus rhamnosus*, *L. plantarum*, and *Bifidobacterium longum* are found to be effectively neutralizing heavy metals in vitro. Besides this, these probiotics also act as antioxidants. Probiotic such as *L. plantarum* CCFM8610 is capable to reduce intestinal absorption of heavy metals and reduces metals deposition in liver and reversing hepatocellular damages due to heavy metal toxicities.^{99,100} Another dietary option against heavy metal-induced hepatotoxicity is use of algae as it contains good amount of vitamin C, vitamin E, carotene, etc. which help to reduce heavy metal-induced oxidative stress.¹⁰¹ High dietary supplementation of protein was also found to be effective in liver metabolism against nickel-induced toxicities.⁶

6.2 Hypoxia, Liver Function, and Dietary Supplementation

It has been found that supplementation of vitamins C and E on hypoxic rats improves hepatic glutathione level as compared with only hypoxia-exposed rats. It may be due to antioxidant vitamins C and E protect thiol status in the liver from hypoxia

injuries.²⁰ Antioxidant vitamins such as vitamins C and E also protect hepatocellular reduction of GSH-Px due to hypoxia exposure by decreasing phospholipid hydroperoxides in the cell membrane and prevent further lipid peroxidation.²⁰ These two antioxidant vitamins usually conjugate with GSH-Px and are able to decrease phospholipid hydroperoxide in liver to inhibit lipid peroxidation.¹⁰² Results show that vitamin C and vitamin E are oxidized by ROS and RNS generated by hypoxia exposure in liver tissues. During combating with these TOS and RNS, tissue produce superoxide, hydroxyl, peroxy, and nitroxide radicals, as well as nonradical reactive species such as singlet oxygen, peroxy nitrite, and hypochlorate. These scavenging actions truly prevent lipid peroxidation, DNA and protein damage in liver. These antioxidants further enter into mitochondria and guard it from oxidative stress-induced damages. It must be noted that mitochondria of living cells including hepatocytes generate lots of intracellular ROS, and vitamins C and E supplementation defend mitochondrial genome.¹⁰³ Study shows that hypoxia exposure leads to decrease of hepatic concentration of vitamin C which may be due to overutilization of vitamin C by the liver tissues to counteract altered oxygen microenvironment in liver.¹¹ It was noticed that supplementation of vitamin E modifies altered oxygen-sensitive VEGF protein expression in hepatic tissues of hypoxic rats which may be through NOS2. In addition to direct cellular oxidant injury by hypoxia exposure, ROS and RNS may constitute signals regulating by either protein function through reversible oxidation and/or nitrosation of protein SHs or gene expression, in the hepatic sinusoid. Normally nitric oxide (NO) is synthesized by NOS2 gene expression and produced RNS in liver due to hypoxia-exposed low-oxygen microenvironment. Such low-oxygen microenvironment in hepatocytes, Kupffer cells, and endothelial cells generate redox-sensitive transcription factor NF- κ B.¹⁰⁴ Study also revealed that the hepatoprotective effect of vitamins C and E under conditions of hypoxia appears to be due to its influence on the functional activity of adrenal glands. It was reported that these antioxidant vitamins enhanced noradrenaline-mediated activity in hypoxia through an iodoacetic acid-sensitive pathway.¹⁰⁵

6.3 Heavy Metals, Hypoxia, and Liver Functions—Dietary Supplementation

Heavy metals such as nickel or lead and hypoxia exposure in liver tissues damage its integrity and develop hepatic malfunctions through ROS and RNS regulatory system. Interestingly, the toxic manifestation for both heavy metals and hypoxia in hepatic tissues are common by nature, i.e. increasing production of ROS and RNS subsequently increase expression of HIF-1 α . It was found that HIF-1 α which expresses in tissue exposed to hypoxia as adaptive mechanism is important to regulate metabolism in liver and kidney.¹⁰⁶ Furthermore, it is noticed that HIF-1 plays an important role to develop fatty liver and hepatic fibrosis. It is also noticed that hypoxic area in fibrotic liver due to heavy metals or chronic hypoxia exposure localized with VEGF expression in hepatocytes and HSCs.¹⁰⁷

The possible mechanism by which vitamins C and E counteract HIF-1 α transcription factor expression may be through regulating/inhibiting ROS formation and indirectly controlling over production of RNS. Hypoxia- and heavy metal treatment-induced HIF-1 α gene transcription actually facilitate VEGF gene expression in hepatocytes to improve adaptability against chronic sustained hypoxia and metal-induced cellular hypoxia in physiological system.¹⁰⁸ Reports suggested existence of a feedback mechanism between ROS production and HIF-1 α in metabolically active tissues, although this link is a complex phenomenon which involves oxidative phosphorylation in response to hypoxia or heavy metals.¹⁰⁹ Furthermore, it is noticed that oxidative phosphorylation in metabolic tissues modulate not only ROS but also oxygen redistribution and consumption by interfering HIF-1 α degradation pathways and over expression of endogenous antioxidant enzymes.¹¹⁰

6.3.1 Heavy Metals, Hypoxia, Vitamin C and E Supplementation—Liver Histopathology

The author's laboratory shows histopathological changes in nickel- and lead-treated rat liver with or without supplementation of vitamin C and E (Fig. 26.7A–G).

Fig. 26.7C and D shows the effect of vitamins C and E supplementation on nickel-treated rat liver histopathology. It shows that the hepatic parenchymal tissue architecture is maintained normal, which is composed of numerous hexagonal to pyramidal “lobules.” Each lobule consists of a central vein from which the hepatic plates radiate outward toward the portal areas; three to five portal triads are located at the periphery of the lobule containing branches of bile duct, portal vein, and hepatic artery; and occasional mononuclear cells. Cords of hepatocytes and blood-containing sinusoids radiate from central vein to the peripheral portal triads. The hepatocytes are large having well-defined cell borders with mild variation in cellular size and shape. The nuclei are round, regular, and vesicular with one to two prominent nucleoli. The cytoplasm is eosinophilic and hypergranular. The portal area appears mildly enlarged with mild proliferation fibrous tissue. The sinusoidal space appears normal with moderate number of Kupffer cells. Central vein shows features of mild dilatation and congestion. No foci of fatty change/hyaline change/degeneration/necrosis/inflammatory reaction are found in vitamins




FIGURE 26.7 Normal (A), nickel sulfate– (B), nickel sulfate with vitamin C– (C), nickel sulfate with vitamin E– (D), lead acetate– (E), lead acetate with vitamin C– (F), and lead acetate with vitamin E– (G) treated rat liver histopathology (45 \times).

C and E supplemented nickel-exposed rats. Results clearly indicate an improvement of hepatic architecture in nickel- or lead-exposed rats supplemented with either vitamin C or vitamin E. [Fig. 26.7F](#) shows hepatic parenchymal tissue with mild distortion of “lobular” architecture which is consisting of a central vein, hepatic plates, and portal areas containing branches of bile duct, portal vein, and hepatic artery in vitamin C–supplemented lead treated rat. The hepatocytes are large having ill-defined cell borders with mild variation in cellular size and shape. The nuclei are round, regular, and vesicular with one to two prominent nucleoli. The cytoplasm is vacuolated to clear type with decreasing eosinophilia containing micro/macro vesiculations. There are mild foci of fatty change and ballooning degeneration and necrosis of hepatocytes in zone 3 (centrilobular) areas. The portal area appears mildly enlarged with mild proliferation fibrous tissue with infiltration of mixed acute and chronic inflammatory cells. The sinusoidal spaces are variably widened with pronounced increase in number of Kupffer cells. Central vein shows features of dilatation and congestion. [Fig. 26.7G](#) shows near normal architecture of liver parenchyma. Hepatocytes appear normal with sinusoidal spaces that appear normal with moderate number of Kupffer cells. Cytoplasm is eosinophilic and central vein appears normal. Results indicate vitamin E is a better protector than vitamin C against lead-induced hepatotoxicities.

The study on experimental rats in the author’s laboratory shows the liver histopathology in hypoxia-exposed and vitamins C and E–supplemented hypoxia-exposed rats ([Fig. 26.8A–D](#)).




FIGURE 26.8 Normal (A), hypoxia exposed (B), hypoxia exposed with vitamin C– (C), and hypoxia exposed with vitamin E–supplemented rat liver histopathology (45 \times).

Fig. 26.8B shows hypoxic liver architecture. The central veins are lined by endothelial cells surrounded by a ring of collagen fibers. The sinusoids are lined by both endothelial cells and Kupffer cells both of which have inconspicuous flattened nuclei and ill-defined cytoplasmic margins. The hepatocytes are polygonal in shape with well-defined borders and appear to be little swollen with mild narrowing of the sinusoidal spaces. Microscopic profile shows normal architecture of liver parenchyma maintained with mild narrowing of the sinusoidal spaces. Cytoplasm is more eosinophilic and hypergranular. Fig. 26.8C showed vitamin C shows normal architecture of liver parenchyma is maintained. Mild narrowing of the sinusoidal spaces with portal triad shows mild proliferation with mild thickening of basement membrane of the blood vessels. No obvious significant changes are noticed. In the case of vitamin E–supplemented hypoxic rat liver, normal architecture of liver parenchyma is maintained but hepatocytes appear to be little swollen with mild narrowing of the sinusoidal spaces. The nucleus is single, is round, and has a fine chromatin pattern with zone 1 to 2 clearly defined amphophilic-prominent nucleoli (Fig. 26.8D). Fig. 26.9A shows effect of vitamin C supplementation on hypoxia-exposed nickel (Ni)-treated rat liver. The experimental studies from the author's laboratory on histopathology of liver clearly indicate near normal architecture of liver parenchyma. Hepatocytes appear normal, and sinusoidal spaces appear also normal with moderate number of Kupffer cells. Cytoplasm is appeared to be eosinophilic. Histopathology also indicates normal central vein with normal portal triad. Results show beneficial effect of vitamin C on nickel-treated hypoxic rat liver as compared with rats without vitamin C supplementation (Fig. 26.6A). In case of vitamin E supplementation on nickel-treated hypoxic rats, mild distortion of "lobular" architecture of liver parenchyma and large hepatocytes with mild variation in cellular size and shape are observed (Fig. 26.9B). Furthermore, liver histopathology reveals that cytoplasm is vacuolated to clear type with decreasing eosinophilia containing micro- and macrovesiculations. There are foci of fatty change and ballooning degeneration and necrosis of hepatocytes in zone 3 (centrilobular) areas and mild proliferation of portal area with fibrous tissue with infiltration of mixed acute and chronic inflammatory cells. Variable widening of sinusoidal spaces are also seen (Fig. 26.9B). Although results indicate a relative beneficial effect of vitamin E supplementation on nickel-treated hypoxic rat liver when compared with nickel-exposed hypoxic rats (Fig. 26.6A), it looked relatively less beneficial when compared with vitamin C–supplemented nickel-treated hypoxic rats (Fig. 26.9A).




FIGURE 26.9 Nickel and hypoxia exposed vitamin C– (A) and vitamin E– (B) supplemented; lead and hypoxia exposed vitamin C– (C) and vitamin E– (D) supplemented rat liver histopathology (45 \times).

In authors' laboratory, liver histopathology of lead (Pb)-treated hypoxic rats supplemented with vitamins C and E was also done. Results show a normal architecture of liver parenchyma with mild swollen hepatocytes. Mild narrowing of the sinusoidal spaces was also observed. Portal triad shows mild proliferation with mild thickening of basement membrane of the blood vessels. There were no foci of fatty change or necrosis or inflammatory reaction in histopathology of liver observed (Fig. 26.9C). Fig. 26.9D shows the liver histopathology of Pb-treated hypoxic rats supplemented with vitamin E. Mild distortion of “lobular” architecture of liver parenchyma and vacuolated cytoplasm with decreasing eosinophilia containing micro- and macrovesiculations is noticed. Furthermore, mild proliferation of portal area with fibrous tissue with infiltration of mixed acute and chronic inflammatory cells is also found. Central vein shows features of dilatation and congestion. Results definitely indicate a relative beneficial role of vitamin E supplementation on liver histopathology in lead (Pb)-treated hypoxic rats as compared with lead-treated hypoxic rats without vitamin E supplementation (Fig. 26.6B).

7. CONCLUSION

It may be postulated that heavy metals such as nickel (Ni) or lead (Pb) cause serious cellular damages including hepatocellular damages. Interestingly, chronic sustained hypoxia also induces hepatotoxicities. The molecular mechanisms involved in both the cases are similar by nature.

Heavy metals such as nickel or lead induce hypoxia over expressions of HIF-1 α in hepatocellular environment which will be followed by generation of ROS and further expression of VEGF and NOS2 gene in liver. This overexpression of HIF-1 α also alters hepatic glycolytic pathways by changing Glut1, LDH, and PFR genes. All these changes lead to hepatocellular damages (Fig. 26.10). Dietary supplements, especially antioxidants such as vitamins C and E are found to be beneficial as they suppress either metal- or hypoxia-induced hypoxia gene expressions in hepatocytes.




FIGURE 26.10 Heavy metal- and hypoxia-induced molecular mechanisms of hepatotoxicities. Red arrow indicates toxicities and green arrow indicates protection.

ACKNOWLEDGMENTS

The first author greatly acknowledges Life Sciences Research Board, DRDO, Ministry of Defence, Government of India (R&D/81/48222/LSRB-285/EPB/2014 dated 18/7/2014) and VGST, Government of Karnataka (VGST-KFIST/1230/2015-16 Dated 22/6/2016) for providing research grant to him. Author also acknowledges the kind supports of Prof. B.G. Mulimani, former vice chancellor, BLDE University, Vijayapura, India.

REFERENCES

1. Das KK, Dasgupta S. Alteration of testicular biochemistry during protein restriction in nickel treated rats. *Biol Trace Elem Res* 1997;**60**:243–8.
2. Ratcliffe PJ, O'Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. *J Exp Biol* 1998;**201**:1153–62.
3. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. *J Physiol* 2008;**586**:4055–9.
4. Colgan SP, Taylor CT. Hypoxia: an alarm signal during intestinal inflammation. *Nat Rev Gastroenterol Hepatol* 2010;**7**:281–7.
5. Schumacker PT. Current paradigms in cellular oxygen sensing. *Adv Exp Med Biol* 2003;**543**:57–71.
6. Das KK, Dasgupta S. Studies on the role of nickel in the metabolism of ascorbic acid and cholesterol in experimental animals. *Ind J Physiol Allied Sci* 1998;**52**:58–62.
7. Valko M, Morris H, Cronin MTD. Metals, toxicity and oxidative stress. *Curr Med Chem* 2005;**12**:1161–208.
8. Gao N, Jiang BH, Leonard SS, et al. p38 signaling-mediated hypoxia-inducible factor 1 alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. *J Biol Chem* 2002;**277**:45041–8.
9. Galanis A, Karapetsas A, Sandaltzopoulos R. Metal-induced carcinogenesis, oxidative stress and hypoxia signaling. *Mutat Res Genetic Toxicol Environ Mutagen* 2009;**674**(1–2):31–5.
10. Adrian LH. Hypoxia-A key regulatory factor in tumor growth. *Nat Rev Cancer* 2001;**2**:38–47.
11. Das KK, Saha S. Hypoxia, lead toxicities and oxidative stress: molecular interactions and antioxidant (vitamin C) defense. *Curr Signal Transduct Ther* 2014;**9**:113–22.
12. Suzuki T, Shinjo S, Arai T, et al. Hypoxia and fatty liver. *World J Gastroenterol* 2014;**20**(41):15087–97. <https://doi.org/10.3748/wjg.v20.i41.15087>.
13. Hande G, Nuran E. Can antioxidants be beneficial in the treatment of lead poisoning? *Free Radic Biol Med* 2000;**29**(10):927–45.
14. Das KK, Gupta AD, Dhundasi SA, et al. Protective role of l-ascorbic acid on antioxidant defense system in erythrocytes of albino rats exposed to nickel sulfate. *Biometals* 2007;**20**(2):177–84.
15. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. *Proc Natl Acad Sci USA* 1989;**86**:6377–81.
16. Frei B. Efficacy of dietary antioxidants to prevent oxidative damage and inhibit chronic disease. *J Nutr* 2004;**134**:3196S–8S.
17. Kasprzak KS, Diwan AB, Kaczmarek MZ, et al. Effects of ascorbic acid on carcinogenicity and acute toxicity of nickel subsulfide, and on tumor transplants growth in gulonolactone oxidase knock-out mice and wild-type C57BL mice. *Toxicol Appl Pharmacol* 2011;**257**(1):32–7.
18. Maniyar SA, Jargar JG, Das SN, et al. Alteration of chemical behavior of L ascorbic acid in combination with nickel sulfate at different pH solutions in vitro. *Asian Pacific J Trop Biomed* 2012;**2**(3):220–2.
19. Das KK, Buchner V. Effect of nickel exposure on peripheral tissue: role of oxidative stress in toxicity and possible protection by ascorbic acid. *Rev Environ Health* 2007;**22**(2):133–49.

20. Das KK, Jargar JG, Saha S. α -Tocopherol supplementation prevents lead acetate and hypoxia induced hepatic dysfunction. *Indian J Pharmacol* 2015;**47**(3):285–91.
21. Das KK, Das SN, Dhundasi SA. Nickel, its adverse health effects & oxidative stress. *Indian J Med Res* 2008;**128**(4):412–25.
22. Sunderman FW, Kincaid JF. Nickel poisoning. II. Studies on patients suffering from acute exposure to vapors of nickel carbonyl. *J Am Med Assoc* 1954;**155**(10):889–94.
23. Agency for Toxic Substances and Disease Registry (ATSDR). *Toxicological profile for nickel*. U.S. Department of Health and Human Services, Public Health Service, ATSDR. Atlanta, Georgia, USA: U.S. Government Printing Office; 2003. p. 5–16.
24. Weischer CH, Kordel W, Hochrainer D. Effects of NiCl₂ and NiO in Wistar rats after oral uptake and inhalation exposure, respectively. *Zentral Bakteriol Mikrobiol Hyg (B)* 1980;**171**:336–51.
25. Ambrose AM, Larson PS, Borzelleca JR, Hennigar Jr GR. Long term toxicologic assessment of nickel in rats and dogs. *J Food Sci Technol* 1976;**13**:181–7.
26. Bouton CM, Frelin LP, Forde CE, et al. Synaptotagmin I is a molecular target for lead. *J Neurochem* 2001;**76**(6):1724–35.
27. Taylor CT. Mitochondria and cellular oxygen sensing in the HIF pathway. *Biochem J* 2008;**409**:19–26.
28. Kiang JG, Tsen KT. Biology of hypoxia. *Chin J Physiol* 2006;**49**(5):223–33.
29. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. *Proc Natl Acad Sci USA* 1991;**88**:5680–4.
30. Leonard SS, Harris GK, Shi XL. Metal-induced oxidative stress and signal transduction. *Free Radic Biol Med* 2004;**37**:1921–42.
31. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. *J Appl Physiol* 2000;**88**:1474–80.
32. Vengellur A, LaPres JJ. The role of hypoxia inducible factor 1 α in cobalt chloride induced cell death in mouse embryonic fibroblasts. *Toxicol Sci* 2004;**82**(2):638–46.
33. Chun YS, Kim MS, Park JW. Oxygen-dependent and independent regulation of HIF-1 α . *J Korean Med Sci* 2002;**17**:581–8.
34. Tan HH, Fiel MI, Sun Q, et al. Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. *J Immunotoxicol* 2009;**6**(4):266–75.
35. Lin Y-C, Lian I-B, Kor C-T, et al. Association between soil heavy metals and fatty liver disease in men in Taiwan: a cross sectional study. *BMJ Open* 2017;**7**(1):e014215.
36. Sidhu P, Gorg ML, Morgenstern P, et al. Role of zinc in regulating the levels of hepatic elements following nickel toxicity in rats. *Biol Trace Elem Res* 2004;**102**:161–72.
37. Volini F, de la Huerga J, Kent G. Trace metal studies in the liver disease using atomic absorption spectrometry. In: Sunderman FW, Sunderman Jr FW, editors. *Laboratory diagnosis of liver diseases*. St. Louis, MO, USA: Warren H. Green Inc.; 1968. p. 199.
38. Sunderman Jr FW. Nickel. In: Merian E, Anke M, Ihnat M, Stoeppler M, editors. *Metals and their compounds in the environment*. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 1991. p. 841–67.
39. Cave M, Appana S, Patel M, et al. Polychlorinated biphenyls, lead, and mercury are associated with liver disease in American adults: NHANES 2003–2004. *Environ Health Perspect* 2010;**118**(12):1735–42.
40. Berrahal AA, Lasram M, El Elj N, et al. Effect of age-dependent exposure to lead on hepatotoxicity and nephrotoxicity in male rats. *Environ Toxicol* 2011;**26**(1):68–78.
41. Britton RS. Metal-induced hepatotoxicity. *Semin Liver Dis* 1996;**16**(1):3–12.
42. Sunderman Jr FW, Dingle B, Hopfer SM, Swift T. Acute nickel toxicity in electroplating workers who accidentally ingested a solution of nickel sulfate and nickel chloride. *Am J Ind Med* 2007;**14**:257–66.
43. Das KK, Gupta AD, Dhundasi SA, et al. Effect of L-ascorbic acid on nickel-induced alterations in serum lipid profiles and liver histopathology of rats. *J Basic Clin Physiol Pharmacol* 2006;**17**:29–44.
44. U.S. Department of Health and Human Services (DHHS). *Seventh annual report on carcinogens: summary 1994*. Research Triangle Park, NC, USA: DHHS, National Institute of Environmental Health Sciences; 1994. p. 262–9.
45. Cross CE, van der Vliet A, O'Neill CA, Louie S, Halliwell B. Oxidants, antioxidants and respiratory tract lining fluids. *Environ Health Perspect* 1994;**102**:185–91.
46. Rodriguez RE, Misra M, North SL, Kasprzak KS. Nickel-induced lipid peroxidation in the liver of different strains of mice and its relation to nickel effects on antioxidant systems. *Toxicol Lett* 1991;**57**:269–81.
47. Das KK, Das SN, Dasgupta S. The influence of ascorbic acid on nickel induced hepatic lipid peroxidation in rats. *J Basic Clin Physiol Pharmacol* 2001;**12**:187–94.
48. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentration of lovastatin and lovastatin acid. *Clin Pharmacol Ther* 1998;**63**:397–402.
49. Gupta AD, Das SN, Dhundasi SA, Das KK. Effect of garlic (*Allium sativum*) on heavy metal (nickel II and Chromium VI) induced alteration of serum lipid profile in male albino rats. *Int J Environ Res Public Health* 2008;**5**(3):147–51.
50. Tikare S, Yendegiri SM, Dhundasi SA, et al. Protective effect of α -tocopherol against nickel sulfate induced hematotoxicity, hepatotoxicity and nephrotoxicity in male albino rats. *Indian J Physiol Pharmacol* 2013;**57**(03):280–92.
51. Das KK, Das SN, Dhundasi SA. Nickel: molecular diversity, application, essentiality and toxicity in human health. In: Blanc G, Moreau D, editors. *Biometals, molecular structures, binding properties and applications*. New York, USA: Nova Science Publishers Inc.; 2010. p. 33–58.
52. Cartana J, Arola L. Nickel-induced hyperglycaemia: the role of insulin and glucagon. *Toxicology* 1992;**71**(1–2):181–92.
53. Mathur AK, Gupta BN. Dermal toxicity of nickel and chromium in Guinea pigs. *Vet Hum Toxicol* 1994;**36**(2):131–2.
54. El-Saieed ME, Mekawy MM. Nickel toxicity in *Oreochromis niloticus* fish. *J Egypt Soc Toxicol* 2001;**24**:47–54.

55. Ptashynski MD, Klaverkamp JF. Accumulation and distribution of dietary nickel in lake white fish (*Coregonus clupeaformis*). *Aquat. Toxicol* 2002;**58**(3-4):249–64.
56. Sobocka E. Changes in the iron level in the organs and tissues of wels cat fish, silurus Glanis L. Caused by nickel. *Acta Ichthyol Piscat* 2001;**31**(2):127–43.
57. Pereira GJG, Molina SMG, Lea PJ, et al. Activity of antioxidant enzymes in response to cadmium in *C. juncea*. *Plant Soil* 2002;**239**:123–32.
58. Damek-Poprawa M, Sawicka-Kapusta K. Damage to the liver, kidney, and testis with reference to burden of heavy metals in yellow-necked mice from areas around steelworks and zinc smelters in Poland. *Toxicology* 2003;**186**(1–2):1–10.
59. Isojärvi JI, Pakarinen AJ, Rautio A, et al. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. *Epilepsia* 1994;**35**(6):1217–20.
60. Marklund SL. Superoxide dismutase in human tissue cells and extracellular fluids, clinical implication. In: Liss AR, editor. *Free radicals aging and degenerative disease*. New York: Raven Press; 1986. p. 509.
61. Khalaf AA, Moselhy WA, Abdel-Hamed MI. The protective effect of green tea extract on lead induced oxidative and DNA damage on rat brain. *Neurotoxicology* 2012;**33**:280–9.
62. Cadenas E. *Oxidation stress*. New York, NY, USA: Academic Press; 1985. p. 313–30.
63. Baeuerle PA, Baltimore D. NF-kappa B: Ten years after. *Cell* 1996;**87**:13–20.
64. Souza V, Bucio L, Gutiérrez-Rtui MC. Cadmium uptake by a human hepatic cells line (WRL-68). *Toxicology* 1997;**120**:215–20.
65. Fujishiro H, Okugaki S, Kubota K, Fujiyama T, Miyataka H, et al. The role of ZIP8 down-regulation in cadmium-resistant metallothionein-null cells. *J Appl Toxicol* 2009;**29**:367–73.
66. Horiguchi H, Harada A, Oguma E, et al. Cadmium-induced acute hepatic injury is exacerbated in human interleukin-8 transgenic mice. *Toxicol Appl Pharmacol* 2000;**163**:231–9.
67. Marth E, Burt S, Jelovcan S. Influence of cadmium on the immune system description of stimulating reactions. *Cent Eur J Public Health* 2000;**8**:40–4.
68. Ahmed M, Akhter MJ, Alhadlaq HA, et al. Comparative cytotoxic response of nickel ferrite nanoparticles in human liver HepG2 and breast MFC-7 cancer cells. *Chemosphere* 2015;**135**:278–88.
69. Jungermann K, Kietzmann T. Oxygen: modulator of metabolic zonation and disease of the liver. *Hepatology (Baltimore, Md.)* 2000;**31**:255–60.
70. Nieminen AL, Gores GJ, Wray BE, et al. Calcium dependence of bleb formation and cell death in hepatocytes. *Cell Calcium* 1988;**9**:237–46.
71. Sewerynek E, Reiter RJ, Melchiorri D, et al. Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin. *Hepato-gastroenterology* 1996;**43**:898–905.
72. Tanaka H, Yamamoto M, Hashimoto N, et al. Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. *Cancer Res* 2006;**66**:11263–70.
73. Ju C, Colgan SP, Eltzschig HK. Hypoxia-inducible factors as molecular targets for liver diseases. *J Mol Med* 2016;**94**(6):613–27.
74. Alchera E, Tacchini L, Imarisio C, et al. Adenosine-dependent activation of hypoxia-inducible factor-1 induces late preconditioning in liver cells. *Hepatology* 2008;**48**:230–9.
75. Guo JY, Yang T, Sun XG, et al. Ischemic postconditioning attenuates liver warm ischemia-reperfusion injury through Akt-eNOS-NO-HIF pathway. *J Biomed Sci* 2011;**18**:79.
76. Nishiyama Y, Goda N, Kanai M, et al. HIF-1alpha induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice. *J Hepatol* 2012;**56**:441–7.
77. Byrne CD. Hypoxia and non-alcoholic fatty liver disease. *Clin Sci* 2010;**118**(6):397–400.
78. Nieminen AL, Saylor AK, Herman B, et al. ATP depletion rather than mitochondrial depolarization mediates hepatocyte killing after metabolic inhibition. *Am J Physiol* 1994;**267**:C67–74.
79. Gores GJ, Nieminen AL, Wray BE, et al. Intracellular pH during “chemical hypoxia” in cultured rat hepatocytes. Protection by intracellular acidosis against the onset of cell death. *J Clin Invest* 1989;**83**:386–96.
80. WHO. *National policy on traditional medicine and regulation of herbal medicines*. 2005.
81. Goyer RA, Clarkson TW. Toxic effects of metals. In: Klaassen C, editor. *Casarett and Doull’s toxicology: the basic science of poisons*. 6th ed. New York, NY, USA: McGraw-Hill Health Professions Division; 2001. p. 822–6.
82. Prasanthi R, Devi CB, Basha DC, et al. Calcium and zinc supplementation protects lead (Pb)-induced perturbations in antioxidant enzymes and lipid peroxidation in developing mouse brain. *Int J Dev Neurosci* 2010;**28**:161–7.
83. Ryu DY, Lee SJ, Park DW, et al. Dietary iron regulates intestinal cadmium absorption through iron transporters in rats. *Toxicol Lett* 2004;**152**:19–25.
84. Djukić-Čosić D, Ninković M, Maličević Z, et al. Effect of magnesium pretreatment on reduced glutathione levels in tissues of mice exposed to acute and subacute cadmium intoxication: a time course study. *Magnes Res* 2007;**20**:177–86.
85. Basha DC, Rani MU, Devi CB, et al. Perinatal lead exposure alters postnatal cholinergic and aminergic system in rat brain: reversal effect of calcium co-administration. *Int J Dev Neurosci* 2012;**30**:343–50.
86. Das KK, Dhundasi SA, Das SN. Hexavalent chromium and its effect on health: possible protective role of garlic (*Allium sativum* Linn). *J Basic Clin Physiol Pharmacol* 2011;**22**(1–2):3–10.
87. Vimal V, Devaki T. Hepatoprotective effect of allicin on tissue defense system in galactosamine/endotoxin challenged rats. *J Ethnopharmacol* 2004;**90**(1):151–4.
88. *Garlic: Nature’s amazing nutritional and medicinal wonder food*. P.O.Box 160, Pleasant Grove, UT 84062: Woodland Publishing Inc.; 1995. p. 5–25.
89. Weil A. *Natural health, natural medicine*. Boston: Houghton-Mifflin Company; 1990. p. p237.
90. Simon JA, Hudes ES. Relationship of ascorbic acid to blood lead levels. *JAMA* 1999;**281**:2289–93.
91. Goyer RA, Cherian MG. Ascorbic acid and EDTA treatment of lead toxicity in rats. *Life Sci* 1979;**24**:433–8.

92. Nemmiche S, Chabane-Sari D, Guiraud P. Role of α -tocopherol in cadmium-induced oxidative stress in Wistar rat's blood, liver and brain. *Chem Biol Interact* 2007;**170**:221–30.
93. Reddy SY, Pullakhandam R, Kumar BD. Thiamine reduces tissue lead levels in rats: mechanism of interaction. *Biometals* 2010;**23**:247–53.
94. Shi J, Maguer ML. Lycopene in tomatoes: chemical and physical properties affected by food processing. *Crit Rev Food Sci Nutr* 2000;**40**:1–42.
95. Pires VC, Gollücke A, Ribeiro DA, et al. Grape juice concentrate protects reproductive parameters of male rats against cadmium-induced damage: a chronic assay. *Br J Nutr* 2013;**110**:2020–9.
96. Mantur VS, Sommanavar MS, Yendegiri SM, et al. Ameliorating effect of black tea extracts on cadmium chloride –induced alteration of serum lipid profile and liver histopathology in rats. *Indian J Physiol Pharmacol* 2014;**58**(2):128–32.
97. Haleagrahara N, Jackie T, Chakravarthi S, et al. Protective effects of Etlingera elatior extract on lead acetate-induced changes in oxidative biomarkers in bone marrow of rats. *Food Chem Toxicol* 2010;**48**:2688–94.
98. Dewanjee S, Sahu R, Karmakar S, et al. Toxic effects of lead exposure in Wistar rats: involvement of oxidative stress and the beneficial role of edible jute (*Corchorus olitorius*) leaves. *Food Chem Toxicol* 2013;**55**:78–91.
99. Halttunen T, Collado M, El-Nezami H, et al. Combining strains of lactic acid bacteria may reduce their toxin and heavy metal removal efficiency from aqueous solution. *Lett Appl Microbiol* 2008;**46**:160–5.
100. Tian F, Zhai Q, Zhao J, et al. Lactobacillus plantarum CCFM8661 alleviates lead toxicity in mice. *Biol Trace Elem Res* 2012;**150**:264–71.
101. Goldhaber SB. Trace element risk assessment: essentiality vs. toxicity. *Regul Toxicol Pharmacol* 2003;**38**:232–42.
102. Sneddon AA, Wu HC, Farquharson A, et al. Regulation of selenoprotein GPx4 expression and activity in human endothelial cells by fatty acids, cytokines and antioxidants. *Atherosclerosis* 2003;**171**(1):57–65.
103. Sagun KC, Carcamo JM, Golde DW. Vitamin C enters mitochondria via facilitative glucose transporter 1 (glut-1) and confers mitochondrial protection against oxidative injury. *FASEB J* 2005;**19**(2):1657–67.
104. Korashy HM, El-Kadi AO. The role of redox-sensitive transcription factors NF-kappaB and AP-1 in the modulation of the Cyp1a1 gene by mercury, lead, and copper. *Free Radic Biol Med* 2008;**44**(5):795–806.
105. Kelly MJ, Richardson W. Possible mechanisms for the protective action of alpha-tocopherol in vascular hypoxia. *J Auton Pharmacol* 1996;**16**(2):87–95.
106. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. *Proc Natl Acad Sci USA* 1995;**92**:5510–4.
107. Novo E, Cannito S, Zamara E, et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. *Am J Pathol* 2007;**170**:1942–53.
108. Das KK, Nemegouda SR, Patil SG, et al. Possible hypoxia signaling induced alteration of glucose homeostasis in rats exposed to chronic intermittent hypoxia - role of antioxidant (vitamin C) and Ca2+ channel blocker (cilnidipine). *Curr Signal Transduct Ther* 2016;**11**(1):49–55.
109. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. *Curr Opin Genet Dev* 2010;**20**:51–6.
110. Bell EL, Klimova TA, Eisenbart J, et al. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. *J Cell Biol* 2007;**177**:1029–36.

Dietary Interventions in Liver Disease

Foods, Nutrients, and Dietary Supplements

Edited by Ronald Ross Watson and Victor R. Preedy

Dietary Interventions in Liver Disease: Foods, Nutrients, and Dietary Supplements provides valuable insights into the agents that affect metabolism and other health-related conditions in the liver. It provides nutritional treatment options for those suffering from liver disease. Information is presented on a variety of foods including herbs, fruits, soy, and olive oil showing that changes in intake can change antioxidants and disease-preventing nonnutrients, affecting liver health and/or disease promotion. This book serves as a valuable resource for biomedical researchers who focus on identifying the causes of liver diseases as well as food scientists targeting health-related product development.

Key Features:

- Provides information on agents that affect metabolism and other health-related conditions in the liver.
- Explores the impact of composition, including differences based on country of origin and processing techniques, to highlight compositional differences and their effect on the liver.
- Addresses the most positive results from dietary interventions using bioactive foods to impact liver disease, including reduction of inflammation and improved function.



ACADEMIC PRESS

An imprint of Elsevier
elsevier.com/books-and-journals

ISBN 978-0-12-814466-4



9 780128 144664